id
stringlengths 36
36
| title
stringlengths 0
391
| funder
stringclasses 125
values | beneficiary
stringlengths 3
1.44k
| source_id
stringlengths 0
41
| abstract
stringlengths 6
4.76k
| funding_scheme
stringclasses 411
values | label
class label 8
classes |
|---|---|---|---|---|---|---|---|
gen_addfc0a228cc4da7ad61aed1ac37113f
|
Development of a Patient-Facing Portal for the Receipt, Interpretation and Tracking Utility of Pharmacogenetic (PGx) Data
|
NIH
|
GENOMIND, INC.
|
1R43HG013068-01A1
|
ABSTRACT Selection of medication for mental illness is generally through trial-and-error, with high rates of adverse reactions and sub-optimal efficacy. Pharmacogenetic (PGx) data is thus of particular benefit to facilitate selection of safe and effective medications and is cost effective, decreases resource utilization, and improves patient engagement, with the potential to overcome medication non-adherence. Nevertheless, in the field of psychiatry, patients' familiarity with PGx remains low, demonstrating the need for improved patient-facing PGx materials. The objective of this project is to enhance sustained patient engagement with their genomic information by: a) increasing patient understanding of PGx results by developing a consumer-focused patient report; and b) facilitating patient-provider communication and shared decision making using PGx-guided medication selection on an ongoing basis by increasing patient self-reporting of psychiatric symptoms using regularly administered psychometric scales that are communicated to healthcare providers in real time. This ongoing self-reporting will serve as the entry point to discussions regarding changes to medication regimens, which will be explained to patients using the consumer-focused PGx report. Ongoing and consistent patient-provider communication is known to reinforce patient engagement, further encouraging patient use of the tracking system. Provider use will be encouraged through the billing codes available for remote patient monitoring. This project has three Specific Aims. Aim 1 is to develop a PGx report that is more accessible to individuals without a biomedical background. The Professional PGx assay report will be adapted using the AHRQ Health Literacy Universal Precautions Toolkit, following which a user comprehension study will be conducted to assess understanding of the report by lay individuals. Aim 2 is to integrate outcome tracking scales within the patient portal to support voluntary tracking of patient outcomes longitudinally and ongoing shared decision making with healthcare providers. For this aim, diagnosis-specific psychometric scales will be integrated into the patient platform, together with a patient reminder system that will send text/email reminders to patients every 2 weeks with a link to the psychometric scales, as well as a reminder system for a designated community member to further encourage patient engagement. An alert system will also be developed to notify patients and designated community members if scores change by >30% between evaluations, prompting the patient to speak to their healthcare provider. User acceptance testing (UAT) will be performed to verify that the systems operate as intended. Aim 3 is to develop an application programming interface (API) to report patients’ longitudinal psychometric scoring directly to the healthcare provider portal to facilitate patient-provider communication and ongoing PGx-guided medication choice. A provider alert system based on patients’ self-reported outcomes, including indications of suicidality, will also be developed, followed by UAT. Successful project completion will, for the first time, combine longitudinal patient outcome tracking and PGx guidance, for both patients and providers, in the mental health field. NARRATIVE In the field of mental health, pharmacogenetics is of particular benefit to facilitate the selection of safe and effective medications, and has the potential to improve patient engagement. Nevertheless, patients' familiarity with pharmacogenetics in psychiatry remains low, demonstrating the need for improved patient-facing materials. This project aims to enhance sustained patient engagement with their genomic information by developing a patient-facing interpretation of a professional pharmacogenetic report to increase patient understanding of pharmacogenetic results, and by facilitating patient-provider communication and shared decision making regarding pharmacogenetic-guided medication selection on an ongoing basis.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_75cb2cb6f33523dde4349d9b6317f4bd
|
Optimized Ratiometric Voltage-Sensitive Dyes for Cardiac Research, Safety Pharmacology
|
NIH
|
POTENTIOMETRIC PROBES, LLC
|
1R44GM152985-01A1
|
Project Summary/Abstract Potentiometric Probes The overall goal of this Phase II SBIR project is to commercialize tools, invented by the founders of Potentiometric Probe, LLC, for high-fidelity optical recording of electrical activity in cardiac cells, tissues, and whole hearts. Potentiometric Probes develops organic voltage-sensitive dyes (VSDs) that convert the changes in voltage across cell membranes to visible changes in fluorescence. Instead of individual electrodes, this technology enables the use of sensitive high-speed cameras, where each pixel can be considered an electrode, for massively parallel high throughput screening, or for high-resolution spatiotemporal maps of electrical signal propagation. Importantly, our VSDs are unique in enabling dual-wavelength ratiometric recording of electrical activity; this is particularly important for cardiac studies because it eliminates contraction-induced motion artifacts, permitting high-fidelity records of the action potential waveform. Human stem cell-derived cardiomyocytes (hiPSC-CMs) and tissues derived from them are increasingly being used for research and development purposes, including screening new drugs for cardiotoxicity, and in the future may be used for “personalized medicine” and the analysis of patient-derived cells. We believe high throughput recording of accurate action potential waveforms from hiPSC-CMs and tissues will be a major market for the proposed technology. Ultimately, the technology may also be applied clinically for high-resolution imaging of action potential propagation in the heart. In this proposal, Potentiometric Probes will synthesize a set of stable, non-toxic ratiometric VSDs with a broad selection of spectral windows, allowing accurate recordings even from beating hearts. The performance of these VSDs will also be fully characterized and validated for their compatibility with sensitive cell lines for both long-term and high-throughput recordings. Project Narrative Potentiometric Probes Potentiometric Probes is developing fluorescent dyes that convert electrical signals of heart cells and tissue into optical signals that can be recorded with cameras. These probes allow researchers to screen drugs rapidly for cardiotoxicity, as well as to study how electrical signals are generated and propagate in the heart, providing insights into mechanisms of genetic diseases and links to cardiac arrhythmias and failure.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_39dd62502f3638ecad9694ed905b089d
|
A micronized electrostatic precipitator for next-generation respiratory protection against pathogenic aerosols
|
NIH
|
HENLEY ION, LLC
|
5R44AI174405-02
|
PROJECT SUMMARY Many pathogens, such as severe acute respiratory coronavirus 2 (SARS-CoV-2) and Mycobacterium tuberculosis, spread via aerosol transmission and inflict global public health and economic consequences. SARS-CoV-2 has infected over 450 million people, led to over 6 million fatalities, and caused major economic losses. The tuberculosis-causing bacterium and longstanding global health enemy, M. tuberculosis, led to an estimated 1.3 million deaths and over 5 billion USD in global spending in 2020 alone. Both of these pathogens, SARS-CoV-2 and M. tuberculosis, impose disproportionate burdens on healthcare workers, who are exposed to airborne pathogens at higher rates than the general population. The current respiratory protection options available to healthcare workers are generally limited to surgical masks and nonoil-95 percent collection (N95) filter-based respirators. N95s are the current gold standard, but these respirators can only properly function when a snug seal on the face of the user causes a pressure drop, which makes breathing more difficult and often leads to compliance issues. These respirators are also not designed to inactivate the pathogens they collect, and their disposable nature generates waste and leaves users susceptible to supply shortages. Thus, the widespread threats of airborne pathogens and the significant limitations of existing protection options necessitate the development of novel strategies to protect healthcare workers from airborne transmission of infectious diseases. Henley Ion’s solution is a next-generation respirator based on a miniaturized form of an electrostatic precipitator (mEP). Henley Ion is the first to leverage the mEP strategy to remove aerosol particles in the context of personal respiratory protection. Rather than relying on a filter, this innovation allows Henley Ion to use mEP to capture and remove aerosol particles as the wearer breathes, needing only the natural velocity of normal breathing. In Aim 1, we will conduct benchtop testing to optimize device performance. We will demonstrate that the particle removal performance of our device matches or exceeds that of an N95 at a range of physiological respiration rates. In Aim 2, we will conduct biological testing to confirm optimized device performance that matches or exceeds the N95 for particle removal of SARS-CoV-2 and M. tuberculosis. We will measure particle removal at differential air flow rates and using discrete particle size distributions, and we will assess any residual viable pathogens in the device. Together, these steps will optimize the Henley mEP respirator and confirm its efficacy against both viral and bacterial pathogens, supporting the commercialization of this novel protective strategy to address the extreme need during the present pandemic and for infectious diseases more broadly. PROJECT NARRATIVE Many infectious diseases, including COVID-19 and tuberculosis, are spread via airborne pathogens that lead to global economic and public health tolls with disproportionate impacts on healthcare workers. Current strategies to protect healthcare workers from airborne pathogens include surgical masks and N95s, but these options have significant limitations in their efficacy, availability, or ease-of-use. By miniaturizing an aerosol particle removal technology called electrostatic precipitation, Henley Ion will provide a comfortable, reusable next-generation respirator that can protect the wearer from airborne pathogens by removing aerosol particles as the wearer breathes.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_77f62ddd5c5eeee7b18d5081ed738874
|
Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety Testing
|
NIH
|
GREENSTONE BIOSCIENCES, INC.
|
1R44HL170756-01
|
PROJECT SUMMARY Cardiotoxicity is a leading cause of early and late-stage drug attrition during pharmaceutical development. The FDA now mandates that all new drugs be tested for cardiotoxicity before entering clinical trials. However, there needs to be a safety screening platform that can swiftly detect cardiotoxicity cost-effectively, even before investing too much time and resource in a drug development pipeline. This is further complicated by genomic susceptibility in the population and how they respond to drugs. A tool that can incorporate the influences of sex, ethnicity, and genetic background can provide accurate data on the safety and efficacy of drugs and stratify patient populations to identify responders versus non-responders. In this SBIR grant, we propose to mitigate this issue by providing pharmacogenomics and precision medicine platforms using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Our product is a kit comprising 100 unique and ethnically diverse iPSC lines with equal sex representation. We aim to develop and validate this tool as a surrogate in vitro model for predicting drug toxicity in patient groups at high risk for drug-induced arrhythmia. The study will use the “cell village” platform to co-culture 10 different patient-specific iPSC lines simultaneously. We will scale this up by multiplexing data from 100 different donors to identify cell-type-specific expression quantitative trait loci (eQTL) using single-cell RNA sequencing (scRNA-seq) and whole genome sequencing (WGS). As a proof-of-principle, we will also assess inter-individual and intra-individual variability in responses to the chemotherapeutic agent doxorubicin. Finally, Greenstone Biosciences, Inc is a biotechnology company located at the Stanford Research Park. Greenstone uses latest advances in clinical genomics, computational biology, and patient-specific iPSCs to understand pharmacogenomics and to accelerate drug discovery. NARRATIVE All new drug candidates must be screened for potential cardiac toxicities before being given to patient. Current drug screening technologies fail to consider the differences between men and women, and differences between different ethnic groups or the fact that people with genetic cardiac abnormalities account for most drug failures; this results in an enormous cost in terms of late-stage drug development failures and patient morbidity/mortality. Greenstone Biosciences has the world's largest collection of induced pluripotent stem cell lines, and the purpose of this application is to develop a subset of these into a validated panel for drug screening and drug discovery that for the first time reflects the heterogeneity of the population at large.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_6db8540cf43f58e1bb0a36e65e72a718
|
An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery
|
NIH
|
FESARIUSTHERAPEUTICS, INC.
|
5R44AR082787-02
|
PROJECT SUMMARY/ABSTRACT Due to the inability of the dermis to regenerate on its own, large full thickness skin loss cannot be restored naturally. The current gold standard treatment involves autologous tissue transfer in which the patient serves as their own donor, which may be challenging due to limited availability of full thickness skin donor sites and donor- site morbidity. Dermal Replacement Scaffolds (DRS) aim to recreate dermis, thereby preventing wound contraction. However, because currently available DRS lack unique cues to guide cell infiltration, they may fail to vascularize sufficiently. The critical barrier to progress in this field is to create a scaffold that 1) promotes rapid cellular infiltration and angiogenesis as required for neodermal formation in full thickness wounds, and 2) increases the incidence and quality of healing in both typical/healthy wounds and difficult to heal sites. To address this significant clinical gap, Fesarius Therapeutics, Inc. is developing DermiSphere™, an innovative DRS product that will regenerate dermis in full thickness skin loss wounds much faster (≤7 days, i.e. >75% faster) than the regeneration achieved using the market-leading DRS product, Integra®. Once dermis has regenerated it can be covered with a thin epidermal skin autograft, yielding skin that is more flexible, functional, and resilient than wounds healed with split thickness skin grafts alone. The commercialization of DermiSphereTM is expected to improve clinical practice in the surgical fields where full thickness skin loss is common including, but not limited to, trauma, burns, infection and post oncologic reconstructive surgery, by significantly decreasing the time required to achieve a healed wound in a scenario of large full thickness skin loss, which will directly result in decreased patient suffering as well as lower expenditure of valuable health care resources. Our preliminary data suggests that the current DermiSphere™ formulation will support all these unmet clinical scenarios. We have demonstrated in a swine model of full thickness skin loss that DermiSphere™ successfully supports complete split thickness skin graft (STSG) take when the two components are applied simultaneously. In addition, a small animal model of full thickness skin loss showed that DermiSphere™ supported rapid and sustained lateral as well as vertical cell invasion, resulting in successful STSG “take” in challenging cases of wound beds with avascular portions and was able to revascularize templates up to 3mm thick. We have recently brought the DermiSphere™ dermal regenerative template formulation to design freeze using a cGMP-material based formulation that is terminally sterilized and are fast progressing in our technology transfer to a contract manufacturing organization. The overall objective of this Direct to Phase II SBIR is to complete a powered, clinically relevant large animal study (Aim 1), screen the DermiSphere™ product in challenging wounds (Aim 2), perform biocompatibility testing (Aim 3), and perform user validation studies (Aim 4). Completion of these Aims will result in the advancement of DermiSphere™ technology towards 510(k) approval and first in human studies. NARRATIVE When autologous tissue is not available or split thickness skin grafts alone are used, full thickness skin loss may not heal or will heal by contracture of the surrounding skin. Current treatment approaches including engineered off the shelf products have significant limitations, including slow, inconsistent, and inadequate tissue formation, hence impaired wound healing. The commercialization of DermiSphereTM is expected to improve clinical practice in surgical fields where full thickness skin loss is common including, but not limited to, trauma, burns, and post- oncologic reconstructive surgery, by significantly decreasing the time required to achieve a healed wound, as well as increasing the thickness of the regenerated dermis in a scenario of full thickness skin loss.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_09149bdf1267b14e3a5bfaf3828fc760
|
Metalloenzyme binding affinity prediction with VM2
|
NIH
|
VERACHEM, LLC
|
5R44GM150323-03
|
Project summary: It is estimated that 40 to 50% of known enzymes can be characterized as metalloenzymes, while currently only 7% of FDA-approved drugs in the United States target this class of protein. This is despite the fact that there are many dozens of already identified metalloenzyme targets involved in virtually every therapeutic area, including anti-inflammatory, antibiotics, antivirals, anticancer drugs, and more. This is in large part because the already very difficult drug design requirement to maintain/increase the potency of an initial ligand (drug-like molecule) while improving/maintaining its target selectivity and pharmacokinetic properties, is made even harder by the complicated and often non-intuitive nature of metal-ligand and metal-protein interactions. Accurate molecular modeling predictions of metalloenzyme-ligand binding affinities, then, would be highly impactful in pharmaceutical industry drug research and development programs, because they would allow R&D scientists to carry out computational experiments drastically reducing the number of expensive and time-consuming bench experiments required to overcome the difficult metalloenzyme inhibitor design challenges they face. However, currently available molecular modeling approaches are unable to make predictions reliable enough to do this. Docking and scoring methods are able to determine, in many cases, the pose of inhibitors in metalloenzyme active sites, but they cannot correctly rank candidate inhibitors in order of binding affinity as they lack the required detail in their energy models. Recently, free energy-based methods have advanced to the point of providing reliable binding affinity predictions for many non-metal protein-ligand series and can, therefore, help speed ligand discovery efforts for these systems. They cannot provide good binding affinities for metalloenzyme-ligand systems though, because to-date they are all entirely based on classical forcefields, which fundamentally limits the accuracy of their descriptions of metal-ligand and metal-protein interactions. This is due, in part, to lack of inclusion of important polarization and charge transfer effects, but it is also because the complex electronic structure, which metals often exhibit, is intrinsically quantum mechanical. This fast-track SBIR proposal will address this by developing a new and unique molecular modeling software tool called Mzyme-QM-VM2, which will provide reliably accurate binding free energies for metalloenzyme- inhibitor complexes by a novel combination of statistical mechanics and highly scalable quantum chemistry methods. This software will be based on mining minima free energy calculation methodology and will be developed as an extension of VeraChem's VM2 free energy software platform. Project narrative Metalloenzymes have been identified as drug targets in virtually every therapeutic area, including anti-inflammatory, antibiotics, antivirals, and anticancer, but the complicated nature of metal interactions with potential drug molecules makes the already difficult drug development process even harder for this class of targets. This project aims to develop a software tool that can accurately predict the binding affinities of metalloenzymes and potential drug molecules, and therefore help research scientists more quickly discover drug candidates suitable for preclinical testing and beyond. Currently available molecular modeling methods are unable to make accurate enough predictions to help scientists with the design of metalloenzyme-targeting drugs; therefore, the proposed project will provide a new capability with significant impact on the development of treatments for human disease.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_464949287b12c43efb29a7e389749fde
|
Non-invasively extendable megaprosthesis
|
NIH
|
GRANITE MEDICAL, LLC
|
5R44AR083875-02
|
ABSTRACT This project is the development of a non-invasively extending distal femur replacement (DFR) for children and adolescents subsequent to bone tumor resection. Each year in the US there are 200-250 malignant bone tumor diagnoses in the distal femurs of patients 15 years and younger. With advances in chemotherapy, limb salvage surgery utilizing a megaprosthesis has increasingly become the treatment of choice. For growing patients these megaprostheses are required to extend so they can “grow” as the contralateral limb grows. Only one non-invasively lengthened DFR is FDA approved to treat these patients. The implant is actuated with a large electromagnetic appliance in a clinical setting. It is exceedingly complex and the average revision rate has been reported at 48%, including revisions for: insufficient lengthening capacity, lengthening mechanism failure, implant fracture, aseptic loosening and infection. MRI is contraindicated and the implant is extremely expensive. Our device is non-invasively, manually extended by pressing on the patient's skin. It's designed for a significantly reduced complication rate, the mechanism is simple and robust, it's MRI compatible and can be lengthened at home for a more gradual growth and constant leg length equality. It is capable of up to 240% of the extension that its sole US competitor offers and is easier and less expensive to manufacture so it can be offered at a reduced price to a greater population. The specific aims of the project are to (1) complete the implant design, (2) design specialized surgical instruments for implantation and (3) conduct non- clinical bench testing in preparation for FDA submission. PROJECT NARRATIVE This project is the development of a non-invasively extending distal femur replacement for children and adolescents undergoing bone tumor resection for maintaining limb length equality. Each year in the US there are 200-250 malignant bone tumor diagnoses in the distal femurs of patients 15 years and younger. Our device is simple, robust, MRI compatible, can be extended more gradually at home, has far more extension capability and is designed for a reduced complication rate when compared to its sole US competitor.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_58a66f80ff06f613ab0e85db947a4a23
|
FEDER - HN - SAS LES GRANDS CHENES - CREATION OF AN INJECTION METHANIZATION UNIT
|
Kohesio
|
LES GRANDS CHENES
|
https://linkedopendata.eu/entity/Q3681805
|
The natural region of Vexin offers diversified agricultural deposits but still used in methanization: cattle manure, slurry, beet pulp, intermediate energy crops (rye, corn), vegetable oils, cereal dust. The vast majority of these substrates will come from the 3 partner farms in the project as well as neighboring farms and local companies. 90% of the total volume is located within a 20 km radius around the methanization site. Only wheat grains, potato pulp and waste come from a maximum radius of 100 km (200t). This local supply makes it possible to present a very good carbon footprint. A forecast assessment of greenhouse gas (GHG) emissions was carried out with the aim of comparing the GHG impact of the current situation of processing agricultural by-products to the GHG impact of the future situation including the site of valorization of these same by-products. The calculations were carried out using the DIGES software on the basis of 24,600 t of gross inputs allowing a saving of approximately 4,000 tonnes of CO2 eq. In addition to the origin of the deposit, the project leaders wanted to be fully part of the territory by integrating the ecological transition contract of Seine Normandie Agglomération. The project is one of the 26 actions of this ambitious contract since it provides for carbon neutrality of the territory in 2040. This ecological transition contract was signed on February 7, 2020 between the State (State Secretariat attached to the Ministry of Ecological Transition) and the agglomeration.
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_6cdf51812f6e8004658ba9705ebe86e0
|
FEDER - JOHNSON&JOHNSON - Nerveskin
|
Kohesio
|
JOHNSON ET JOHNSON SANTE BEAUTE FRANCE
|
https://linkedopendata.eu/entity/Q3681810
|
The existence of sensitive skin is both internal (stress, lack of sleep) and external (pollution, UV, etc.) in origin. However, few cosmetic solutions are offered to relieve sensitive skin. The main discomfort of sensitive skin is pruritus: an unpleasant sensation leading to the need to scratch and to fairly debilitating inflammatory skin pathologies associated with a dysregulation of neuro-cutaneous interactions. 1/3 of the world population (2.5 billion people) has been subject to notable itching, localized to one part of the body or even generalized. Also nearly 10-50% (0.75-3 billion people) consider they have sensitive skin regardless of whether it is itchy or not. The dermo-cosmetics market is still young and growing. In almost 15 years, it has more than doubled. Western Europe represents 60% of the global market compared to 22% of the total beauty market. It is therefore necessary to develop cosmetic products adapted to relieve/treat these associated skin disturbances. “Everyone” consumers buy through pharmacies and supermarkets. Pharmacies are at the heart of the dermocosmetics market. In Western Europe, they represent, with drugstores, 25% of skin care sales. In the United States as in Brazil and China, pharmacy does not always benefit from the same attractiveness as in Western Europe. Consumers prefer to turn more to drugstores, shopping malls and department stores. To study pruritus or sensitive skin, and evaluate active ingredients, there are a multitude of cellular models. It is rather easy to find primary human skin cells, however for neurons there is no economical or practical solution. The techniques used for the identification of plant raw materials with soothing properties are limited to a phenotypic approach (without a mechanism of action targeted at a particular receptor).¿ The mechanisms of action of existing products are often associated with a reduction in skin inflammation or a restoration of the barrier function. ¿Few ingredients have been developed with an approach targeting sensory neurons for a more complete and lasting action. ¿The formulation of new products is today time-consuming, expensive and not universal. These products have a limited action and their mechanism of action is very little described. The NERVESKIN project aims to develop cosmetic products for sensitive skin, using natural molecules, tested and validated on re-innervated skin explants.
|
Smarter Europe / Research and innovation / Technology transfer and university-enterprise cooperation primarily benefiting SMEs
| 0business_rnd_innovation
|
gen_553d88fc3c76c822e0e89b7db5f0b41d
|
FED FCT 16E00128 Age'Inn Testing a telemetry tool among the general population, in a semi-rural environment
|
Kohesio
|
AGE'INN CONSULTING
|
https://linkedopendata.eu/entity/Q3673469
|
The company Age'Inn Consulting specializing in e-health - from the Hom'agence group working in the field of gerontology and innovation serving seniors - is joining forces with the company H4D, which develops e-health solutions, and with the Dozulé Town Hall with the aim of testing a telemetry tool among the general population, in a semi-rural environment. This experimental project aims to be sustainable and duplicable, the deployment of which is planned for one year from March 2016, will take place in Dozulé, a dynamic town in Calvados, whose attractive territory represents around 6,000 inhabitants. At the origin of this initiative, Mr Jacques Pleurmeau (President of the Hom'agence group) and Dr Marc Goullet de Rugy (ENT and Director of the e-health branch of Hom'agence), sought an alternative to the problem of access to care for population, through cooperation between different actors. Indeed, our region has been facing medical desertification for several years, and despite numerous initiatives, this problem remains serious. Access to specialized medicine is particularly increasingly difficult for Norman users living in an area far from large cities and/or having mobility difficulties. Dozulé elected officials have proactively positioned themselves as partners in this project, facing the problem of medical desertification experienced by residents; also with the aim of improving the attractiveness of the territory. Allowing users to more easily access specialized examinations, close to their homes, while preserving their comfort thanks to the use of innovative tools, is the main objective of this project. If the tool used has an important place in this project, the treating physician remains at the heart of the ecosystem. The general practitioners of Dozulé were involved in the reflection from the start. It is a real networking of various actors which allowed the creation of this experimental project. The implementation of an innovative and duplicable solution within the population's care pathway requires real knowledge of the territory and its inhabitants. The tool must adapt to the doctor's practice, in a context where medical time is limited. The tool deployed by H4D, the Consult Station, was designed to allow the patient to access an in-depth medical consultation, with recordings of numerous complex parameters, access to which is, for some, non-existent routinely in general medicine. For more than 20 years, the Hom'agence group has done everything possible to ensure quality care for dependent elderly people, with the desire to put technology at the service of people. The project presented in this document is the result of a reflection combining the experience of care for the senior population and the search for technological solutions that have proven their usefulness, for local care of users.
|
Smarter Europe / Information and communication technology / ICT solutions addressing the healthy active ageing challenge and e-Health services and applications (including e-Care and ambient assisted living)
| 0business_rnd_innovation
|
gen_f2ef0c72b57d8d23524dee59836cabcb
|
FEDER-ENR INSTALLATION OF A WOOD BOILER ROOM IN RANES -TE 61
|
Kohesio
|
TERRITOIRE D ENERGIE ORNE
|
https://linkedopendata.eu/entity/Q3680228
|
As part of renovation work on municipal buildings, the municipality of Rânes, through transfer of skills, wanted to rely on TE 61 to install a wood energy solution
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_42016160ee0291fdcb1c0d29b73cf199
|
FEDER - STARNAV - DOME 6 PROJECT
|
Kohesio
|
SARL STAR NAV
|
https://linkedopendata.eu/entity/Q3673380
|
Any severe motor disability affecting speech and motor skills of the hands and legs, of various origins (degenerative neurological disease, public road accident leading to quadriplegia, stroke, malformation or rare disease) isolates the person and drastically reduces their autonomy, preventing them from finding or regaining a family, social or even professional position in our current society. In people suffering from a degenerative disease with a serious prognosis, the reduction in mobility, associated with a reduction in cognitive abilities, the increasing difficulty in communicating with the family circle and nursing staff constitutes both a handicap and moral suffering. Maintaining the relationship with the family and the home care team at the end of life is becoming more and more difficult, and has the ultimate consequence of making it impossible to keep the patient at home. In the context of end-of-life support, the need for oral expression (symptoms/complaints, pain, feelings, help, fear) with loved ones or the healthcare team is crucial in the medical and psychological care of patients. This problem concerns certain diseases such as Amyotrophic Lateral Sclerosis or other neurodegenerative and/or neurovascular diseases which deprive the patient of this essential communication. During the progression of these diseases, maintaining a certain degree of autonomy is essential for patients, and this maintenance can involve controlling the environment through home automation (i.e. light, television, radio, etc.). Communication systems have undergone a revolution in recent decades. Today we communicate with our contemporaries via vectors that were unknown 20 years ago: emails, SMS, blogs, tweets (Bigot, 2012). These new technologies have opened up great prospects for populations of people with physical disabilities. In particular, they have made it possible to significantly improve their autonomy thanks to specific interface systems, technical aids, voice synthesis and recent advances in computerized home automation. However, these tools are generally dedicated to a single use and often remain very expensive. In addition, there persists a lack of access to IT tools and particularly to the Internet, which is a factor of disruption and social isolation. Some studies have also shown that computers have an important role in maintaining professional activities in quadriplegic people (Brocharda, 1987). The wave of touch screens is currently depriving some interested parties of multiple practical functionalities. To meet this need, a contactless man-machine interface solution called HEAD PILOT was developed by the company STARNAV. Based on the analysis of the user's head movements through image processing, this system makes it possible to make any computer device equipped with a webcam accessible. STARNAV took advantage of this technological advance to develop a multimodal system for home automation control, access to communication and access to computer applications and Internet links. The PICTOCOM system thus gives its users open access to the digital world. STARNAV wanted all developments to be carried out in collaboration with disabled people and patients with loss of autonomy as part of a clinical trial plan.
|
Smarter Europe / Research and innovation / Technology transfer and university-enterprise cooperation primarily benefiting SMEs
| 0business_rnd_innovation
|
gen_5a3a9ffc003399341fe4f7c3a7444911
|
TLN SNI EUR 18E02019 COSYWORK
|
Kohesio
|
COSYWORK
|
https://linkedopendata.eu/entity/Q3681290
|
To date, on the Paris-Rouen axis, there are only two coworking spaces in Eure located in Louviers and Evreux. Facing Vernon Giverny station and a two-minute walk from the city center, we are creating COSYWORK, the first coworking space in Vernon. 1 month, for 1 year, 7 days a week and 24 hours a day, we offer open work spaces, closed offices, friendly spaces and meeting rooms over more than 300m.
|
Smarter Europe / Competitiveness of SMEs / ICT Services and applications for SMEs (including e-Commerce, e-Business and networked business processes), living labs, web entrepreneurs and ICT start-ups)
| 0business_rnd_innovation
|
gen_039940ec46016dd9851a3c31ec71f1cf
|
2020 - HN20.21/ Support for business consolidation in Upper Normandy in 2020 and 2021
|
Kohesio
|
ASS POUR DROIT A L INITIATIVE ECONOMIQUE
|
https://linkedopendata.eu/entity/Q3681969
|
Adie is recognized by public authorities as a reliable partner in the implementation of public policies in favor of employment and business creation. Adie participated in the consultation process set up as part of the new 2014-2020 programming at the national level through INPAP. The association is aimed at people excluded from the traditional banking system, to whom it offers solutions (effective financial tools, long-term relationship of trust with an advisor, adapted training modules) to find their way back to employment. In the 1st quarter of 2020, Pôle emploi in Normandy recorded 159,300 job seekers. This number is up 0.9% compared to the 4th quarter of 2019. The departments of Eure and Seine Maritime saw their unemployment rate increase on average by 0.9 points. Normandy can count on the significant number of business creations in order to maintain a significant employment rate in the region. However, the COVID19 crisis is causing significant damage to the economic fabric and the sustainability of businesses. Increased mobilization of Adie to encourage initiative in business creation and preserve the vitality of small businesses already in operation is of great importance. In line with the objectives of the operational program, the operation aims to contribute to increasing the number of business creators supported in the departments of Eure (27) and Seine Maritime (76) formerly the Haute-Normandie region in 2020-2021. It will also be a matter of supporting already existing businesses to enable them to relaunch after the health crisis. As part of this project, Adie will provide support for business creation projects through support, advice, personalized monitoring, access to financing and work on the project, with a view to creating or consolidating the economic model of micro-enterprises created by business creators in 2020-2021.Creators can be supported by the association at all stages of the life of their project, upstream of its realization until its consolidation with the aim of improving its quality to enable its sustainability.
|
Smarter Europe / Competitiveness of SMEs / SME business development, support to entrepreneurship and incubation (including support to spin offs and spin outs)
| 0business_rnd_innovation
|
gen_3994939038d989b6474982b3d667bc29
|
FEDER - LINEO - NEPFLAX PROJECT
|
Kohesio
|
LINEO
|
https://linkedopendata.eu/entity/Q3680654
|
The innovative NEPFLAX project presented by the companies LINEO and ECOTECHNILIN and UNICAEN, is part of the current context of the boom in Linen on the Composite market. Traditionally used in the textile industry, Linen has found new opportunities in the composite market thanks to properties that make it possible to compete with fiberglass and carbon. The fluctuating price of oil and global warming are factors in favor of plant-based, biodegradable and renewable fibers. Linen for the composite materials market is commonly called Technical Linen to distinguish it from linen for the textile industry market. Technical linen is developing thanks to its mechanical and environmental properties which have several comparative advantages (low density, high specific rigidity, high vibration absorption capacity, thermal and acoustic insulation, biodegradability). Technical linen currently constitutes a real source of innovation in the design, sports & leisure, automobile, aeronautics and academic research sectors. Associated with resins, the technical linen fabric is at the origin of “high performance” composite products: window frames, sports and leisure equipment, automobiles, eco-construction. The LINEO company was created in 2006 with the aim of developing industrial and commercial activities in the long linen fiber sector for the composite market. Relying on a strong R&D policy, LINEO is at the origin of new developments in the world of composites. LINEO designs and manufactures reinforcements from long flax fibers mainly for the automotive, aeronautics, and sports and leisure sectors. LINEO relies on two technologies that it has patented: FlaxTape technology, impregnation technology. ECOTECHNILIN is the French leader in the supply of non-woven products based on natural short fibers. It has been a major player in the flax market for composite materials for over 20 years. Its main activity concerns materials based on non-woven natural fibers (linen, hemp, kenaf, jute, fiberglass). Its production capacity reaches 7000 tonnes per year. In business for more than 20 years, ECOTECHNILIN achieved a turnover of €5.9 million in 2012-2013 which continued to grow and doubled in 3 years with €11.2 million in 2015-2016. This turnover reached €15 million in 2016-2017, 90% of which was exported. UNICAEN has worked in collaboration with the company Linéo since 2007, first in the form of services, then in the form of a partnership (CIFRE, Z.E.Cherif, 2013). UNICAEN obtained the 2010 JEC Award in the biosourced materials category in 2010, as a partner of LINEO, Huntsmann, and Décathlon. His action consisted of carrying out an experiment/numerical calculation dialogue with the aim of increasing the quantity of flax in a tennis racket, the added value of flax being to provide cushioning to the racket for the well-being of the player. The CIMAP PM2E team has therefore specialized in flax fiber and linen-based composites. The know-how acquired extends to all stages of the development of biosourced composites, and at all scales. An independent thesis from the Linéo company will be defended in July 2017 which relates specifically to the analysis of FlaxTape with a width of 40cm. Specific methodologies have been developed to analyze this product; we are mainly interested in the influence of the morphological factors of the reinforcement on the final properties of the associated composites. short fibers.
|
Smarter Europe / Research and innovation / Research and innovation infrastructure, processes, technology transfer and cooperation in enterprises focusing on the low carbon economy and on resilience to climate change
| 0business_rnd_innovation
|
gen_93fadd82b166444d85469173f7cfc66e
|
Support and assistance for VSEs/SMEs in digital transformation
|
Kohesio
|
COMMUNAUTE DE COMMUNES DE GRANVILLE TERRE ET MER
|
https://linkedopendata.eu/entity/Q3680333
|
Not available
|
Smarter Europe / Competitiveness of SMEs / Advanced support services for SMEs and groups of SMEs (including management, marketing and design services)
| 0business_rnd_innovation
|
gen_710f9b858cab31df594603672963943d
|
FEDER MUNICIPALITY OF VIRE CREATION OF BOILER ROOM GREEN SPACE SITE (Copy of file “15E00117)
|
Kohesio
|
COMMUNE DE VIRE
|
https://linkedopendata.eu/entity/Q3673434
|
After responding to a call for projects initiated by the Pays du Bessin in Virois, as part of its territorial climate energy plan, the town of VIRE chose to create a wood boiler room in order to contribute to the development and valorization of the resources of Lower Normandy in terms of renewable energy. Indeed, Biomass is an abundant resource in our region and easily storable and recoverable to ensure heat production. After observing the obsolescence of the heating devices in the horticultural greenhouses and the green spaces service office currently operating on oil and gas, it was quite natural that the Cit'ergie-certified city opted for the installation of a heating method using renewable energy. The choice of creating a wood boiler room as well as a heating network serving the greenhouses emerged as a form of support for the Viroise wood industry because the supplier (Rivières et Bocages) selected is located within the city and will supply the needs for forestry and bocage chips. This solution therefore mobilizes a local resource as well as support for professional integration within our territory, which directly impacts local employment. A technical and economic analysis of the energy needs of the site was carried out, which made it possible to demonstrate that we would have a heating network with a density of 2.05 Mwh/ml, as well as taking into account summer needs thanks to a dynamic thermal simulation. The use of this study will allow the choice of equipment that complies with current regulations for respecting the environment. This project will avoid the release of 125 tonnes of CO2 and will contribute to the reduction of energy consumption.
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_110647f297eb831d1969199f0c734539
|
FEDER - DRONE HOLDING - SYDDRE PROJECT
|
Kohesio
|
DRONE HOLDING
|
https://linkedopendata.eu/entity/Q3681586
|
In recent years, small drones have become increasingly attractive and accessible (purchase, maneuverability, price). Although their use is regulated by law (decree of April 11, 2012 relating to the design and use of civil aircraft which circulate without any person on board), the latter are sometimes used for malicious purposes such as violation of privacy, industrial espionage or intrusion on sensitive sites, civil (nuclear power plants, industrial sites, port areas) or military (communication stations, air defense bases, radar stations), sometimes for destructive purposes. Consequently, the surveillance of public spaces, private properties and sensitive sites has become a major concern for the authorities responsible for ensuring the security of people and property or respect for privacy. Application in the military field: OPEX protection is a field which regularly experiences significant technological advances. Passive protection remains a priority but it is increasingly combined with active protection which should make it possible to quickly detect dangers (PSR&T 2009). The concept of detection has been the subject of a patent application No. 1653532 in France and EP172955.7 in Europe. Confidentiality has been imposed by the DGA. Problem: Monitoring sensitive industrial sites against intrusion requires designing and implementing a passive detection system that does not emit signals likely to disrupt the installations to be monitored. Systems have already been designed using radars, direction finders, passive vision systems or acoustic measurements. However, most of these techniques come up against the small size of drones and require the use of advanced signal processing techniques to differentiate relevant radar (Doppler) echoes (from the drone) from those that are less relevant (other objects) or to isolate the acoustic signature. These systems are generally very expensive, complicated to install quickly and very bulky. Furthermore, their effectiveness is not always demonstrated. Illegal flights are mainly carried out by individuals specializing in immersion flights (First Person View). The heads of security organizations met (security services of sensitive sites, STAT, DGAC, DGSI) are unanimous on the subject. DRONEXTR and ARELIS have already developed a drone detection solution called V1. This solution is functional but does not make it possible to detect new generations of drones (notably WIFI drones). In addition, the existing solution does not offer the functionalities expected by customers: geolocation of the drone identification of the drone number
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_f742cbd30230a24f6a52d98825df6b83
|
FEDER - APRIL - PROTEIN PROJECT
|
Kohesio
|
AVRIL
|
https://linkedopendata.eu/entity/Q3681720
|
Strong demographic growth and nutritional transitions will lead to an increase in global demand for proteins by 2030 estimated at 40% (source: FAO), or an overall annual growth of more than 7%, to meet both animal and human food needs. The development of the global protein market will necessarily involve an increase in the supply of products offered and a diversification of their origin (animal, plant, new resources). In this context, Avril has decided to implement a strategic innovation partnership with DSM in 2016 for the development, production and marketing of a new ingredient, rapeseed protein isolate intended for human food (food ingredients containing more than 90% protein).
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_498542e91b51e0076a4cfef6fcfad3cd
|
FEDER - SOGET - ONE4YOU PROJECT
|
Kohesio
|
SOGET
|
https://linkedopendata.eu/entity/Q3681452
|
SOGET, leader of this project, is a world-class player in the development and implementation of multimodal one-stop shops. Its vision is to serve the fluidity of port operations, by organizing for the various public and private operators, intelligent, shared and instantaneous management of information relating to logistics chains. ISEL and SOGET wish to join forces in order to respond to the major structural challenges of international flows: Digital culture is changing the perceptions and practices of the companies making up the communities (whether they are users, customers or partners). Large flow operators (shipowners, terminal operators, logisticians, manufacturers) base their strategies on the development of digital solutions in order to be more competitive in their markets and to provide value to the end customer. The logistics ecosystem is changing with flow operators constantly seeking productivity gains and fluidity of trade. Conversely, sovereign actors (customs authorities, port authorities and other administrations) seek to control and secure the flow of goods. To respond to these two movements which can oppose each other, multimodal port and airport one-stop shops must reinvent themselves and combine facilitation and security of trade. On the other hand, the one-stop shop market is experiencing unprecedented development. As part of the WTO BALI agreements, an agreement on trade facilitation was ratified and came into force on February 22, 2017. The latter aims to accelerate the movement, release and customs clearance of goods at borders. Its entry into force marks the start of a new phase of reforms intended to facilitate trade around the world and creates important momentum for trade and the multilateral trading system as a whole. At the same time, new technologies are emerging, such as artificial intelligence which opens up new fields of application in logistics. These systems are capable of learning, making decisions, automating tasks, and carrying out global flow monitoring tasks based on exchange histories. Innovation being the pillar of research and development of any software publisher, SOGET launched in 2014 the reflection of the e-maritime 2 project "Artificial Intelligence at the service of logistics which was included in the CPER 2014-2020 as a priority digital project in transport. The e-maritime 2 project is part of the dynamic of the trade facilitation agreement of the World Trade Organization, the massification of one-stop shops has across the world, and the emergence of national operators of vital importance. This new complex environment requires the contribution of artificial intelligence to the service of tomorrow's logistics in a context of globalization at the level of operators and sovereign authorities. Artificial intelligence will be the true digital revolution in the service of trade facilitation. The e-maritime 2 project will consist of the development of new information systems for management, control, targeting and monitoring of international supply chains based on artificial intelligence technologies, the digital intensities of the Internet of Things and cyber-security linked to the dematerialized power of the Cloud. Already, a prospective study has been carried out with a certain number of companies following an internal reflection between SOGET and ISEL which made it possible to determine various concrete expectations complementary to the S)ONE one-stop shop. These new services are grouped under the title ONE4YOU and represent one of the first components of e-maritime2. ONE4YOU thus aims to determine the research and development roadmap
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_c7d6a757f3eb6aa9ce5601129c0d09cb
|
FEDER - GAEC DES ESTIVES - CREATION OF AN INJECTION METHANIZATION UNIT
|
Kohesio
|
GAEC DES ESTIVES
|
https://linkedopendata.eu/entity/Q3680166
|
The GAEC des ESTIVES is managed by 3 partners: Madame and Monsieur LEGAY and their eldest son. Two full-time employees and one seasonal worker are employed there. The agricultural operation is made up of: - an SAU of 400 ha including 195 ha of sales crops, 80 ha of fodder corn and the balance in temporary and natural meadows; - a herd of 160 HOLSTEIN dairy cows with a quota of 1,400,000 liters and 70 heifers raised per year.Mr. and Ms. LEGAY also own a cider business on a personal basis with 300 to 800 tonnes of processed apples per year. The methanization project is the result of the installation of a new partner and the expansion of the agricultural operation. The methanization unit will be built by the GAEC des ESTIVES, and will be located in the extension of the farm at a place called "Le Bourg", in Cerisy-Belle-Etoile. biomethane will be injected into the public gas distribution network managed by GrDF, which is located 3 kilometers from the project. Customers have reserved an injection capacity of 115 Nm3 of biomethane per hour. The objectives sought are mainly: - The establishment of an activity closely linked to agricultural production; - Local treatment of organic agricultural waste (10,900T per year); - Diversification of economic activities to have additional income; - The desire to be autonomous in terms of upkeep and maintenance of the future methanization site; - The ability to have an activity with a medium-term price guarantee; - The overall consistency of the operating system; - The possibility of strengthening the installation of the new partner.
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_2f1210d3ecb1f2b5456a4d87cb905f25
|
FEDER - SINAY - AIMS PROJECT
|
Kohesio
|
SINAY
|
https://linkedopendata.eu/entity/Q3673613
|
AIMS is a collaborative project between two Norman SMEs, SINAY and SoyHuCe and the GREYC laboratory at the University of Caen. It is a project certified by the Pôle Mer Bretagne Atlantique. AIMS was also the winner of the SME-Biodiversity Initiative call for projects from ADEME and the General Investment Commission. In this context, a first co-financing was allocated for part of SINAY's tasks. This request for FEDER co-financing aims to finance the other project partners and finance the SINAY tasks not supported by ADEME. AIMS is at the TRL6 development stage, and is therefore very close to its market. At the European Union level, a study on blue growth commissioned by DG/MARE (2012) estimated the value of the environmental studies market in all of its applications (MRE, port development, oil and gas industry, marine protected areas, etc.) at €4 billion per year, with an increasing trend and an estimated expansion potential of 5%. 6 (1 being the lowest potential and 6 the strongest). In the context of Normandy alone, with its 3 wind farm projects, 2 tidal turbine pilot farms, its 3 Large Maritime Ports, its 510 fishing vessels, its network of marine protected areas, this market represents more than 30 million euros. The problems encountered in this market are linked to the diversity and volume of data. This raises issues such as collection, storage, calculation capacity, standardization of methods of analysis, evaluation and interpretation of results. From a logistical and economic point of view, this translates into heavy and sometimes rather artisanal field logistics, and high implementation costs. Indeed, according to the European Commissioner for Maritime Affairs and Fisheries, Maria Damanaki, “the data collected during campaigns can stimulate knowledge and innovation as long as engineers and scientists manage to find the means to collect, disseminate, merge and exploit this data efficiently and quickly. At present, this is generally not the case. The AIMS project aims to provide an adequate response to the issues described above, by offering an innovative approach to effectively integrate the collection, storage, processing and visualization of marine data. The project consists of developing a turnkey integrated technological solution associated with a range of innovative services. The offers are intended to be applied to different areas linked to the sustainable management of blue growth. AIMS is therefore made up of two main pillars. A product integrating a network of data acquisition systems, a storage and calculation platform, a bank of algorithms for analyzing noise levels and the associated environmental risk A range of services, such as the deployment and maintenance of acquisition systems, storage and calculation, training, and the carrying out of studies on the marine environment. With this disruptive offer, it is envisaged to generate by 2020 a turnover of 6.8 million euros (22% of the market Normand), to create 16 jobs in the region and maintain 20.
|
Smarter Europe / Research and innovation / Technology transfer and university-enterprise cooperation primarily benefiting SMEs
| 0business_rnd_innovation
|
gen_238a979d2d3ba82076a747e327a18f2a
|
FEDER HN - SAS METHA DES BOSQUETS - Creation of an injection methanization unit
|
Kohesio
|
METHA DES BOSQUETS
|
https://linkedopendata.eu/entity/Q3681676
|
• Project initiated since October 2017 by a group of 11 farmers from BOIS HEROULT (76750), BOSC EDELINE and the surrounding municipalities, most of which belong to CUMA DES BOSQUETS. • Supported from the outset by the municipality of BOIS HEROULT which covered the costs of the feasibility study, carried out by SOLAGRO in June 2018, and the GRDF study carried out in August 2018 for connection to the natural gas distribution network, the project is today led by the SAS “METHA DES BOSQUETS”, created in March 2019 by the 11 farmers, a GRDF retiree, Yves TROLET, municipal councilor in BOIS HEROULT and the company ENERFA, developer of the project. The President of METHA DES BOSQUETS, Hubert LESEIGNEUR, is a farmer and municipal councilor in BOIS HEROULT.
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_49542e5555c39effa139957de8f3329f
|
CRESCENDO - plan d'actions 2016-2017 - FEDER
|
Kohesio
|
CRESCENDO
|
https://linkedopendata.eu/entity/Q3673690
|
The operation of CAEs and the status of salaried entrepreneur are recognized and regulated by the ESS law of July 31, 2014 and the decree of October 27, 2015. Many people wish to create their activity to, at a minimum, create their own job: the motivations are generally discouragement in the job search, the prospect of never finding a job (over 50 years), the difficulty of finding a first job for young people, the wish to leave the company in which the employee no longer finds satisfaction. This type of project leader masters the technique of their profession but does not have all the skills necessary for the development of their activity (knowing how to sell) and for monitoring the activity (knowing how to manage)
|
Smarter Europe / Competitiveness of SMEs / Advanced support services for SMEs and groups of SMEs (including management, marketing and design services)
| 0business_rnd_innovation
|
gen_5da4d9849a5faee36c185af6052b97e7
|
FEDER - NUSBAUMER - DRIFT PROJECT
|
Kohesio
|
NUSBAUMER SN
|
https://linkedopendata.eu/entity/Q3681669
|
The Nusbaumer company is a partner in this collaborative project which also brings together the following partners: the Saverglass Group which also has a site in Normandy (Tourres et cie in Le Havre) and the Lamih laboratory at the Polytechnic University of Hauts de France. Saverglass and the mold maker Nusbaumer, some thirty kilometers away, jointly develop and produce the majority of the tools following empirical methods which rely primarily on the know-how of their personnel.Nusbaumer, an SME of 40 people (€4.7 million turnover in 2018) manufacturer of Glassware Molds and Models, specializes in the production of tools for the wine and spirits sector, through its long-standing collaboration with Saverglass. Currently Nusbaumer is the only mold maker in the Glass Valley able to meet the needs of Saverglass, all of his colleagues focusing on the perfumery business, with very different specificities and tool dimensions. The glassware mold manufacturing business in France faces competition from companies located in countries with low labor costs. Furthermore, companies in the sector are closely linked to local demand and their activity is often single activity / single client, which represents a risk. In this context Nusbaumer, whose activity is more than 90% associated with Saverglass, must strengthen its technical skills and know-how in order to be recognized as the essential manufacturer of glassware molds for high-end spirits, allowing it to increase its competitiveness and differentiate itself from its competitors. Thus, through this project, the partners work together to make the tools more reliable (in particular the material), to optimize the design of existing molds to respond to production issues, to evaluate the relevance of new material grades (which Nusbaumer can/must exploit if the relevance is proven) and to support Nusbaumer to enable it to understand the influence of its production processes on the performance of the molds (thermal, dimensional, machine stability, lifespan, etc.). This project aims for Nusbaumer to support its partners to improve reliability and better control the shaping of their glass bottles, part of the process for which Nusbaumer is a preferred supplier.
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_af42fd8e08299218778bff2a9a4b7465
|
FEDER - Heatself - Secure-Hop Project
|
Kohesio
|
HEATSELF
|
https://linkedopendata.eu/entity/Q3681757
|
As part of this collaborative project, HEATSELF is a partner. The other partners are the company NICOMATIC, PME in Rhône Alpes and the CEA-LIST. AIRBUS-HELICOPTERS is a client who proposed specifications common to all players in aeronautics: fire detection. HEATSELF was consulted for its skills in the field of materials and for its work in the field of heat-sensitive materials. The need for aeronautics is the reliability and security of our planes and helicopters. The safety devices are linear thermal sensor type and are developed by an American company. Airbus wants Europe to have the skills to meet this need which is becoming more and more critical. The specifications therefore relate to the detection of a fire in a helicopter engine. HEATSELF will have to develop a temperature sensor cable capable of informing the pilot if there is a strong rise in temperature locally along this cable. The HEATSELF sensor cable will be associated with electronics called a reflectometry analyzer capable of communicating with the cable and translating the temperature of the cable sensitive to the temperature.
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_c303804fadc78bd997d1c8d54116270c
|
ENR - FEDER BN - STE CAENNAISE REAL ESTATE DEVELOPMENT - WOOD BOILER ROOM LA CAENNAISE SOCIAL HOUSING
|
Kohesio
|
SOCIETE CAENNAISE DEVELOPPEMENT IMMOBILIER
|
https://linkedopendata.eu/entity/Q3673661
|
Not available
|
Greener, carbon-free Europe / Low-carbon economy / Renewable energy: biomass
| 0business_rnd_innovation
|
gen_be87a95a27007369ef68697b876e4568
|
Open access for Innovator Award
|
Wellcome Trust
|
SurgiBox Inc
|
HRCS22_11948
|
No abstract available for this analysis
|
HRCS Research Uncodeable
| 0business_rnd_innovation
|
gen_c0a150fd066bc38fc7a396d7884795bc
|
Exploratory development of Aleta-001 (CD19-CD20 bridging protein) for a first in human clinical trial
|
Cancer Research UK
|
Aleta BioTherapeutics
|
HRCS22_12194
|
Chimeric antigen receptor (CAR) therapy involves isolation of patient T cells followed by viral-mediated gene insertion and T cell expansion in culture. The resulting CAR T cells are infused into the patient. Patient T cells that express an anti-CD19 scFv chimeric antigen receptor (anti-CD19 CAR) can elicit durable and curative responses against CD19-positive B cell malignancies. However, up to 60% of patients who initially achieve a beneficial clinical response to this therapy relapse afterwards. Relapses typically happen in the first few months after therapy is administered. Relapses occur when the CAR T cell population does not achieve optimal expansion and persistence after administration. T cell expansion and persistence require the availability of the CD19 antigen on the tumor cells and on normal B cells. In some patients the initial T cell expansion fails to eradicate all of the tumor cells, so they achieve a partial clinical response or, a complete clinical response is achieved, but CAR T cell number in circulation is below optimal. These patients will relapse. In some patients the expression of CD19 is lost from the tumor cells, which therefore become invisible to the CAR T cells. These patients will also relapse. Aleta-001 is a CD19-anti-CD20 biologic designed to optimize anti-CD19 CAR T cell activity by creating a novel source of CD19 on the tumor cells. All NHL patient tumor cells are CD20-positive and the biologic binds to this CD20 with high affinity. In the case of suboptimal CAR T cell expansion, the biologic provides higher CD19 antigen density on the targeted cells to optimally stimulate the CAR T cell population. In the case of CD19 antigen loss, the biologic replaces CD19 via anti-CD20 binding, providing a de novo antigen source. This biologic is the only therapeutic specifically designed to optimize anti-CD19 CAR T cell therapy. The modality offers the clinician and patient a ready solution that can be administered by injection to optimally activate or reactivate the CAR T cell therapy the patients has already received. The goal of the proposed collaboration with CDD is to fund early phase clinical trials at UK cell therapy centers of excellence. The clinical trials of this novel therapeutic will demonstrate safety and measure PD markers of response to treatment. Ultimately this funding will help us improve patient outcomes in the setting of anti-CD19 CAR T cell treatment of advanced B cell cancers.
|
6.1 Pharmaceuticals
| 0business_rnd_innovation
|
gen_a4400c8fd962df44df2cc5a785dc3135
|
Repurposing two JAK inhibitors as a treatment for DMD
|
Duchenne UK
|
AGADA Biosciences
|
HRCS22_16291
|
Test whether treatment with JAK inhibitors (Tofacitinib and Ruxolitinib) improves muscle function and histology in mdx mice.
|
5.1 Pharmaceuticals
| 0business_rnd_innovation
|
gen_dbed77c14c8ce5ed844e399abac92d5d
|
SaddleSpur: Physiology research into providing lower lumber support for cyclists
|
Innovate UK
|
Darius Development Limited
|
HRCS22_21355
|
An innovative bicycle saddle, which provides padded lower lumbar support for enhanced comfort and performance. The patented, redesigned, cycle seat ("SaddleSpur") provides a padded, vertically curved saddle extension, which prevents the coccyx and buttocks from sliding backwards, whereby providing a fulcrum from which the cyclist can transmit more pressure and force through their legs. Whereas every other component of bicycles has been redesigned and re-engineered over the past 100 years, the bicycle seat design has received far less attention. SaddleSpur incorporates some of the latest design features, plus the patented saddle extension, for both male and female cyclists. This "coccyx connection" completes the five touch points of cycling to provide a secure fulcrum to enable more power to be transferred through the legs, whereby increasing cycling performance and reducing the potential for lower back pain. This research project is designed to identify and quantity the performance improvements of the revised bicycle seat design by a series of structured tests for male and female cyclists over varying distances (10, 20, 40, 60 and 100 miles) with varying undulations. Bio-metric statistics will be recorded for each distance for each cyclist using existing saddle design. and the revised, SaddleSpur, design, and compared to quantify the cardiorespiratory difference, with other bio-metric statistics. The testing, to be conducted by a UK, acclaimed sports medicine academic institution, will be published in scientific and academic journals, and form the basis for an introductory SaddleSpur marketing program early next year - focussed on pleasure, leisure, cycling club enthusiasts, internationally.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_430f5a34e0ce06be1499da7db4251edb
|
Fuelling well-being, self-care and independence for seniors through crowd-based funding stream
|
Innovate UK
|
Deliberate Impact Ltd
|
HRCS22_21358
|
One of the greater challenges in society currently, is the changes in demographics. The number of seniors increases rapidly (absolutely and relatively, that part of the total population), and with this change comes also a natural increase in the need for support. As many of the age-related disorders are created by inactivity, rather than age itself, there is a need to focus on habilitation more than rehabilitation, prevention rather than "repairs", self-care and independence rather than being productive within hospitals. The social care system in the UK is stated to be under severe crisis, with the Covid pandemic amplifying the situation. The Health Foundation estimated already back in 2019 (pre-covid) a shortage of up to £10bn by 2023 if we are to meet the demand pressure of the population, and the continuous cut in budgets for the past 15 years is said to result in deterioration of health and low quality of life for millions of people. The focus of public funds coming into the senior sector is on the sheer basic medicinal and health-related needs, downplaying or ignoring most initiatives and programmes that could have been successful in preventing disorders and health-related problems in the first place - be that physical illnesses or mental challenges. We propose an entirely new approach to funding streams to support initiatives and programmes that will aid seniors to be healthier longer, and hence increase independence and well-being and general quality of life. We will build a revolutionary crowdsourcing - crowdfunding platform for impact and sustainable change. The Takk! platform empowers the crowd to instigate and influence initiatives for making people's lives better. The platform is purpose-driven and it allows for donations, membership and impact investments. This will enable online donations from private individuals which are amplified with matching donations from partners, targeted to the specific initiatives and programmes (available in the platform). In sum this will increase activity and quality of life, and so help seniors to stay independent and healthier longer. By taking part in the initiatives, the seniors will increase self-care and build resilience to illness, whether that is of a physical or a mental nature.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_e1d4f2aa17a67c01044ceb99c1f93c62
|
Bruadar, The Virtual Companion
|
Innovate UK
|
Litha Group Ltd
|
HRCS22_21587
|
This project is to take our research in psycholinguistics and design the architecture for a human-like memory to enrich the quality of human-computer interactions in such fields as mental health issues, loneliness, and neurodegenerative diseases such as Alzheimer's.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_90469802296f8437c9119573369daf64
|
Risk Assessment for Data related Hazards in Healthcare Equipment and Infrastructure
|
Innovate UK
|
Mission Critical Applications Limited
|
HRCS22_21643
|
Modern computer systems increasingly use data to make safety-critical decisions. Healthcare systems are particularly dependent on data, as they act on data flows between organisations, and between healthcare professionals and patients in the community. The rollout of healthcare further into the community introduces additional uncertainty about the quality of the data. Tuus, the trustworthiness of the data itself, and the robustness of the equipment and the computerised infrastructure to incorrect or inappropriately used data, has become vital. The systems need to be designed in such as way as to prevent or reduce the likelihood of harm arising from the very data that is meant to improve clinical safety outcomes. There have already been a number of accidents and incidents across all industrial sectors, including healthcare, where data, as distinct from purely software and hardware, has been a major contributory factor. This problem will get worse as our systems become more dependent on data from diverse sources, more inter-connected, and using data not collected by healthcare professionals. This data might be fed into AI systems and even autonomous systems with wide-ranging consequences, which might not be easily traced back to the erroneous data. The UK Safety Critical Systems Club has created a Data Safety Guidance document, which is widely regarded as describing the current best practice of Data Safety Assessment. This has led to its inclusion in NHS Digital's own guidance on Data Safety. We have developed a proof-of-concept software demonstrator tool under a grant from the Lloyd's Register Foundation, that guides a practitioner through the Data Safety assessment process, and records the analysis and decisions made by the practitioner, to form the core of a Data Safety argument that could be given to a regulator or commissioning organisation. Our current Data Safety tool is industry-agnostic. This project aims to evolve the tool to remove a current restriction, to validate it in the healthcare domain, and understand the customizations that would be needed to deploy it into this domain. We also plan to promote the issues and solutions to Data Safety at some workshops.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_12ef6ac6085fbc892022894fc4088d1a
|
Modular terraced housing for older residents of rural areas
|
Innovate UK
|
Rural Design Centre Limited
|
HRCS22_21849
|
Issues around availability of suitable housing in rural areas are well documented and have become more pressing in recent times. Purchase of homes as second homes and holiday lets has reduced availability and increased prices, whilst the recent trend for relocation from urban areas to desirable rural communities, driven by increased homeworking, has also had an effect. Even before COVID-19, the number of homeless families was increasing rapidly in rural England (CPRE data) and demand outstrips supply. Longer term, ageing demographics of rural areas has increased the volume of housing required for a given population and changed the ideal layout of properties. Older people without families do not necessarily need or desire large properties, which can be more expensive to heat and maintain and may not fit individual access requirements. However, the build rate of bungalows, for example, has been far behind demand. The impact of planning rules and commercial pressures means that bungalow construction has been falling, with an 80% decrease from 2000 to 2020\. Given the challenges around land values, planning and community acceptance of new developments, we need new solutions to this problem. Our premise is that by creating low cost, energy-efficient but desirable single story housing at sufficient density, we can create capacity for older people to move into appropriate accommodation whilst freeing up homes for younger families. The initial thinking is to build on learning from traditional low rise miner's homes and more recent sheltered housing developments but utilise the latest concepts in modular construction to deliver on energy efficiency and cost targets. We envisage a modular courtyard-style development of one and two bedroom terraced homes. Our concept is that the community feel provided by a courtyard development of 10-20 properties will be attractive to the target group whilst still allowing a high enough density of housing to overcome land availability issues and allow use of smaller brownfield sites. The lead organisation is the Rural Design Centre. The Centre was set up as a not-for-profit company with support from key rural organisations like the NFU, CLA, local authorities and LEPs, community networks and business groups to take a new human-centred, design-led approach to rural issues. We use design thinking methodologies to bring together communities, businesses, public authorities and researchers to co-design solutions to rural challenges. We have a team of design associates and innovation managers, with experience of product, service and process design.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_85f04a338fb910435d70633a016ce51f
|
ALIVE: Avatar Learning Impact assessment for Virtual Environments
|
Innovate UK
|
Sublime Digital Limited
|
HRCS22_21909
|
Currently, accurate representation of physical spaces and, especially, human interactions in Virtual Reality (VR)can often feel clunky, unrealistic and require specialist knowledge and development. Our project will explore avatar use through the Unreal Meta Humans tool (an extraordinary new 3D character creation technology), specifically, testing the use of realistic avatars in soft skills training and social interactions. We will use this grant to generate ideas that address this gap in knowledge, and do fast, low-cost prototyping and user testing to further our understanding of the field. We will build and test a variety socially impactful scenarios (ranging in complexity intra- and inter-personal relationships) in VR and attempt to understand how these avatars are perceived. We will investigate whether the realism of the avatar impacts on trust, engagement, and a sense of presence. This work aims to advance the study of artificial social interactions, and guide industry practice. Edify is a platform that combines gaming tech, virtual reality and user generated content to enable accessible, immersive and engaging educational experiences. Educators can teach in virtual environments and deliver immersive lessons remotely - while participants interact and collaborate. Research in the use of avatars in teaching, specifically, immersive education, is sparse. Understanding the challenges from previous research on embodiment and avatars research can help us understand how the benefits of immersive teaching can be enhanced. With the expertise from cutting edge immersive technology (Edify.ac), computer science and psychology (University of Glasgow) we can begin connecting these individual research strands.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_5ed3dbb055d9e1d3731a6d21057fdd4f
|
How might the Xploro application improve the understanding and acceptance of sedation and anaesthesia for child patients and their families
|
Innovate UK
|
Xploro Limited
|
HRCS22_22091
|
Pain associated with procedures can be mitigated but sometimes not eliminated. Children who require repetitive procedures as part of diagnostic or therapeutic interventions may develop peri-procedural fear and anxiety. Mitigating these adverse psychological responses requires developing coping skills that build upon patient and parental preparation. So, what does this mean to the young child that has to undergo a bone marrow biopsy, lumbar puncture as well as MRI of brain and spine to make a diagnosis of acute leukemia? Informing the child what the procedures entail, why they are necessary and what parts may be painful are imperative for assent. The important question is how can we decrease the pre-procedural fear or anxiety for the patient, and is there any potential impact in lessening the stress for parents and siblings? Through the unique use of an artificially intelligent Avatar Guide, 3D augmented reality models and a series of games the Xploro platform has already been shown to reduce anxiety for children undergoing radiological procedures, having blood tests and attending an outpatient's department. We now want to build on that success and collaborate with a leading international institution to examine whether new content has the potential to reduce pre-procedural anxiety for children undergoing sedation and anaesthesia. In this project Xploro will work with the clinical, commercial and user experience teams at University Hospitals, Cleveland to define a scope of work for developing and commercialising a game-based intervention preparing children and their families for the end-to-end journey of a procedural sedation encounter.
|
Missing/Incomplete
| 0business_rnd_innovation
|
gen_d464749c96e98a273794a457492ade6d
|
Gates Foundatoin
|
Manus Bio Inc.
|
INV-026772
|
To develop a bacterial strain that produces artemisinin
|
Community Engagement Grantmaking / Global Health
| 0business_rnd_innovation
|
|
gen_35be53d174505f3fc78eed811664b87e
|
Gates Foundatoin
|
Nutcracker Therapeutics, Inc
|
INV-025870
|
to assess the potential of a novel mRNA manufacturing platform for future pandemic responses
|
Polio / Global Health
| 0business_rnd_innovation
|
|
gen_9d2ca3914dd95aca48683cf9d2d2b1c2
|
Gates Foundatoin
|
Inventprise, Inc.
|
INV-031050
|
to commit additional vaccine production to the COVAX Advance Market Commitment of Gavi, the Vaccine Alliance, a financing mechanism through which Gavi aims to secure equitable access to COVID-19 vaccines for 92 LMIC
|
Global Health and Development Public Awareness and Analysis / Global Health
| 0business_rnd_innovation
|
|
gen_3476e343f5bd90fd96ec101382580216
|
Erosion and Ice Resistant cOmposite for Severe operating conditions
|
European Commission
|
MAIER, S.Coop.
|
CORDIS-685842
|
In the wind power generation, aerospace and other industry sectors there is an emerging need to operate in the low temperature and highly erosive environments of extreme weather conditions. Such conditions mean current materials either have a very short operational lifetime or demand such significant maintenance as to render many applications either very expensive to operate or in some cases non-viable. EIROS will develop self-renewing, erosion resistant and anti-icing materials for composite aerofoils and composite structures that can be adapted by different industrial applications: wind turbine blades and aerospace wing leading edges, cryogenic tanks and automotive facia. The addition of novel multi-functional additives to the bulk resin of fibre reinforced composites will allow the achievement of these advanced functionalities. Multi-scale numerical modelling methods will be adopted to enable a materials by design approach to the development of materials with novel structural hierarchies. These are capable of operating in severe operating environments. The technologies developed in this project will provide the partners with a significant competitive advantage. The modification of thermosets resins for use in fibre composite resins represents both a chemically appropriate and highly flexible route to the development of related materials with different applications. It also builds onto existing supply chains which are represented within the partnership and provides for European materials and technological leadership and which can assess and demonstrate scalability. The partnership provides for an industry led project with four specific end users providing both market pull and commercial drive to further progress the materials technology beyond the lifetime of the project.
|
H2020-EU.2.1.3. / 2.1.3 LEIT - Advanced materials
| 0business_rnd_innovation
|
gen_e395c70834591e75979b3f1ac8853962
|
Saving COOPerative Energy
|
European Commission
|
COOPERATIVAS AGRO-ALIMENTARIAS DE ESPANA U. DE COOP.
|
CORDIS-695985
|
SCOoPE project will work directly with energy-intense agro-food industries to implement cross-cutting and collaborative energy management systems addressed to reduce their energy consumption, and will further spread this knowledge within technicians, businesses managers, and energy and agro-food institutions. The project SCOoPE aims at achieving the challenges of the topic EE 16-2014/2015. Regarding the use of cost-effective energy solutions, the project objective is to reduce energy consumption at a short term in a range between 10% and 15% directly in 81 businesses belonging to the agro-food target sectors of the project (namely crop drying, meat and poultry, dairy, and fruit and vegetables transformation). This reduction must be achieved without any decrease in the production capacity of the companies and maintaining correct socioeconomic and environmental conditions. In order to do that, the project will work with the uptake of specific and cross-cutting innovative technologies and techniques, which efficacy has been proven in other industrial sectors, different from agro-food sector, but that are not yet familiar to project’s target sectors. On the other hand, the project pursues larger savings in the medium term with new affordable energy solutions, specifically by developing the concept of “Collaborative Energy Management Systems”. It will take advantage of complementarities and synergies between analysed industrial sites with similar characteristics and will use them for the improvement of their joint energy efficiency. For this purpose, 6 pilot industrial clusters will be run in order to prove the improvements of total energy consumptions and its associated costs, achieved by using common procedures based on ISO 50.001 and supported by an specific software (Dashboard) developed by the project. All these experiences will be promoted to encourage target groups to reduce their energy consumption, following the example of the directly involved companies.
|
H2020-EU.3.3. / 3.3 Societal Challenges - Energy
| 0business_rnd_innovation
|
gen_0b851e601cc1ae7f5222f61bea28eee3
|
Optimised moulded pulp for renewable packaging solutions
|
European Commission
|
NOVAMONT SPA
|
CORDIS-720744
|
The aim of PULPACKTION project is to develop cellulose-based tailored-to-purpose packaging solutions for specific food and electronic packaging applications which needs medium and high barrier requirement’s and that nowadays are packing in polymer fossil based solutions. This innovation will take advantage of the flexibility in the wet-moulding production of wood pulp based materials. Different types of wood pulp will be combined to prepare slurries for wet-moulding applications. These slurries will be additivated with biopolymers and other bio-based compounds in order to tailor the final properties of the resulting wet-moulded materials. By tailoring the composition of the wet mouldable slurry, a wide range of final properties in the resulting dry material will be achieved. This flexible packaging manufacturing system will be combined with 100% bio-based coatings and films on the cellulose-based substrate. To fulfil the properties required for PULPACKTION’s specific packaging applications using a fully bio-based approach, additional barriers will be implemented onto the wet moulded substrate. For this purpose, new bio-based polymer blends will be optimized. These new blends, containing biopolymers such as thermoplastic starch (TPS), poly (lactic acid) (PLA), other bio-additives, and reinforcements such as microfibrillated cellulose (MFC), will be processed into multilayer films, composites and coatings. In this manner, not only coatings for improved barrier properties, but also 100% bio-based films for packages’ top lids will be produced. Therefore, a final 100% bio-biobased integral packaging solution with similar properties to existing fossil-based packaging solutions will be achieved.
|
H2020-EU.3.2. / 3.2 Societal Challenges - Food
| 0business_rnd_innovation
|
gen_1be0f913837d120f3eac8fa6d79af10e
|
Industrial Feather Waste Valorisation for Sustainable KeRatin based MAterials.
|
European Commission
|
VERTECH GROUP SARL; Centre national de la recherche scientifique; RISE PROCESSUM AB
|
CORDIS-723268
|
According to European Commission, 13.1 million tons of poultry meat was produced only in the European Union (EU-28) in 2014 with an estimated generation of 3.1 million tons feather waste. At present the majority of poultry feathers are converted into low nutritional value animal food or disposed in landfills, causing environmental and health hazards. In this context, the overall objective of KaRMA2020 is the industrial exploitation of such underutilized waste to obtain added value raw materials for the chemical sector: keratin, bioplastics, flame retardant coatings, non-woven and thermoset biobased resins. This will be accomplished through either: i) innovative and sustainable approaches (already patented by some of KaRMA2020 partners), or ii) conventional and economic techniques. The obtained raw materials will be manufactured at industrial scale and further used for the production of novel bio-based products such as: slow release fertilizers, biodegradable food packaging plastics, flame retardant coated textiles and flame retardant thermoset biobased composites. The sustainability of the new raw materials and end-products will be evaluated through LCA assessment. Additionally, an integrated waste management plan will be elaborated to minimize environmental impacts generated by wastes. Communication and knowledge transfer as well as a detailed business plan will allow maximizing overall profitability of KaRMA2020 results. The well balanced composition of the consortium including industry, RTD performers and academia give KaRMA2020 the maximum chance of success.
|
H2020-EU.2.1.5. / 2.1.5 LEIT - Advanced manufacturing and processing
| 0business_rnd_innovation
|
gen_948396de07f9897ced5043afb20e42ec
|
DISRUPTING LITERACY CONTENT CREATION PLATFORM FOR EDUCATORS ENABLING ADAPTIVE AND FLEXIBLE LEARNING FOR KIDS
|
European Commission
|
Myabckit
|
CORDIS-735804
|
This is a re-submission of the last call, having improved the weak points (attached ESR after section 5). The UNESCO found that at least 250 of the world’s 650 million primary school age children are unable to read, write or do basic mathematics even if they are in primary school (130 million). Furthermore, they calculated that the cost of 250 million children around the world not learning translates to a loss for governments of around 120 billion euros annually. myABCKit aims to democratize the access to innovative literacy learning methodologies based on Maria Montessori’s methods (That usually are quite expensive not accesible for everyone). Using new ICT methodologies to revolutionize and empower new kids formal and non-formal education methodologies based on teaching HOW to think instead of WHAT to think. myABCKit is accessible from any device and is based in three main areas around the adaptive learning overall concept: • Content creation tools for educators to be able to personalise content in terms of context, interest, familiarity and language. • New business models around literacy content through a marketplace where educators and schools can monetize their creativity. • Play-based exercises focused on literacy for kids: vocabulary, grammar, reading and comprehension of one or more languages for K-12 students. • Learning analytics foe schools and educators in order to know the evolution and early detection of learning disabilities to improve their academic results by applying adaptive learning. Thanks to myABCKit disruptive app, the market opportunities and the EC support, it is expected to reach over 1 million kids and generate over 100 million EUR in revenues in 2022. Moreover, the results of this project will catapult myABCKit as a leader in the global adaptive e-Learning market, the first play-based literacy-learning app for kids maximizing the benefits of ICT and Montessori’s methodology in a unique, smart and friendly ecosystem.
|
H2020-EU.3.6. / 3.6 Societal Challenges - Europe in a changing world
| 0business_rnd_innovation
|
gen_ca1dbd42c084169b4c0ee423d0ca01d3
|
Fifth Generation Communication Automotive Research and innovation
|
European Commission
|
Volvo Cars
|
CORDIS-761510
|
There are two ongoing industrial trends, one in the mobile communications industry and one in the automotive industry, which are becoming interwoven and will jointly provide new capabilities and functionality for upcoming intelligent transport systems and future driving. The automotive industry is on a path where vehicles are continuously becoming more aware of their environment, due to a permanent increase in various types of integrated sensors; at the same time the amount of automation in vehicles increases, which – with some intermediate steps – will eventually culminate in fully-automated driving without human intervention. Along this path, the amount of interactions increases, both in-between vehicles, as well as between vehicles and an increasingly intelligent road infrastructure. As a consequence, the significance and reliance on capable communication systems for vehicle-to-anything (V2X) communication is becoming a key asset that combined with sensor-based technologies will enhance the performance of automated driving and increase further traffic safety. On the other hand, the mobile communications industry has over the last 25 years connected more than 5 billion people and mobile phones have become part of our daily living. The next step in wireless connectivity is to connect all kinds of devices that can benefit from being connected, with a total of 28 billion connected devices predicted until 2021. It will support the transformation of industries on their journey of digitization. In this step, mobile communications has the ambition to explicitly target the communication needs of vertical industry with corresponding requirements being set for the standardization of 5G until 2020. 5GCAR brings together a strong consortium from the automotive industry and the mobile communications industry, to develop innovation at the intersection of those industrial sectors in order to support a fast, and successful path towards safer and more efficient future driving.
|
H2020-EU.2.1.1. / 2.1.1 LEIT - ICT
| 0business_rnd_innovation
|
gen_7ca98ca9523b7a74ceef489ec0cd7471
|
Innovative compact HYbrid electrical/thermal storage systems for low energy BUILDings
|
European Commission
|
OCHSNER WARMEPUMPEN GMBH; COMSA EMTE
|
CORDIS-768824
|
HYBUILD will develop two innovative hybrid storage concepts: one for the Mediterranean climate primarily meant for cooling energy provision, and one for the Continental climate primarily meant for heating and DHW production. HYBUILD action is a systematic approach for developing operationally integrated thermal and electric components and systems from TRL4 to TRL6 and beyond. The hybrid storage concepts are based on: a compact sorption storage, based on a patented way to integrate an innovative adsorbent material within an efficient high surface heat exchanger, a high density latent storage, based on a high performance aluminum micro-channel heat exchanger with additional PCM layers, and an efficient electric storage. The balancing of thermal and electrical energy flows will be realized by seamless integration of electric building components in a DC coupled system and by efficient conversion and upgrading of electric surplus and renewable thermal energy sources by compression and adsorption heat pumps. The components will be integrated to realize the full-scale hybrid storages (with overall volume between 1 and 2 m3), which will be properly managed by advanced control and building energy management systems (BEMS), able to optimize the interactions between components and district network. Such a configuration will allow reaching energy savings ranging between 20 and 40%, on yearly basis, both in Mediterranean and Continental climate for non-connected and district-connected buildings. HYBUILD hybrid storages will be used to upgrade existing building configurations and monitored in three different demo sites in near-life operation, both for non-connected and district-connected buildings in different climates.
|
H2020-EU.2.1.5. / 2.1.5 LEIT - Advanced manufacturing and processing
| 0business_rnd_innovation
|
gen_69faa52bad81878ffe18802a1226cc60
|
illuMINEation --- Bright concepts for a safe and sustainable digital mining future
|
European Commission
|
VEITSCH-RADEX GMBH & CO OG
|
CORDIS-869379
|
The (European) mining industry is under great pressure due to a number of reasons, e.g. high number of injuries/fatalities and environmental accidents, bad reputation, low commodity prices, depleting resources and decreasing ore grades, etc. The only way to overcome these challenges is to completely “rethink” the process of traditional mining via progressively digitising mining operations and introducing ground-breaking innovations (e.g. remote controlled robots, autonomous drones, novel sensor systems, etc.), accompanied by the extensive use of data analytics and new forms of Industrial Internet of Things (IIoT). illuMINEation will illuminate important digitalization aspects in underground mining operations in order to achieve the next level of safety, environment and economic performance, and to retain and gain a social licence to operate. The project will develop a robust multi-level distributed IIoT platform (including cloud computing & distributed cloud management) that connects via wireless communication with the physical mining world, defined by massively installed low-cost all-embracing sensor networks. Advanced analytical algorithms will support the implementation of powerful, sophisticated automated control systems. Mobile user interfaces, dashboards, augmented and virtual reality as well as digital twins will be utilised for data visualisation and operational control. illuMINEation will ensure that all mining personnel receive the best possible information that the enormous amount of data has to offer, whilst ensuring all data is properly protected via a rigorous cyber security approach. The illuMINEation consortium provides the necessary resources and comprehensive skills and capabilities to operate across organizational boundaries with the aim to bring together the different parts of the entire digital mining business value chain and create cross-industry innovations.
|
H2020-EU.3.5. / 3.5 Societal Challenges - Climate
| 0business_rnd_innovation
|
gen_e64676ab6e3facb8a5dd48b9862e382f
|
Grow your manufacturing business
|
European Commission
|
HOLONIX SRL-SPIN OFF DEL POLITECNICO DI MILANO; University of Oulu; Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
|
CORDIS-951813
|
Better Factory will provide methodology for Manufacturing SMEs to collaborate with Artists to develop new and personalized products. At the same time Better Factory will provide technology for SMEs to become fully connected cyber-physical-systems, transforming them into Lean-Agile production facilities capable of manufacturing new and personalized products alongside existing products. Main results: -_x0001_An Advance Production Planning and Scheduling (APPS) system which can be deployed on a free and open IoT platform at 10% of the cost in 50% less time. APPS will automatically reconfigure the collaborative robots considering the individuality and gender of worker, and will also reduce 10% assets, 25% area, 30% resources, 35% logistics, 40% machines and tools and workplaces, resulting in 13% cost reduction, 15% production increase and 30% time to market. -_x0001_A Marketplace, a one-stop-shop, where Manufacturing SMEs can buy services from Technology suppliers, Artists, CCs, training providers and financial brokers. -_x0001_A portfolio of 16 cross-border Application Experiments by 48 SMEs selected through 2 competitive Open Calls, that will test APPS, SME+Artis collaboration and other services, and leveraging 11M€ of public and private funding becoming success stories. -_x0001_Services, including Technical, Business and Art mentors, infrastructure, training and access to finance. Better Factory network consists of 28 members. 18 DIHs (10 CCs, 8 industry associations), 6 Technology suppliers and 4 service providers for marketing, access to finance, FSTP management and legal framework. Partners are currently engaged in I4MS-Go, DIH², HORSE, L4MS, MIDIH, AMABLE, BOWI, SHOP4CF. Better Factory covers 16 EU countries, 17 regions with 10 of them from EU-13. Better Factory will demonstrate that public funded research can help manufacturing SMEs & Mid-Caps achieve digital excellence and global competitiveness through Lean-Agile production for the manufacturing of new and personalized products.
|
H2020-EU.2.1.1. / 2.1.1 LEIT - ICT
| 0business_rnd_innovation
|
gen_a7a5bd5a8a405b52cc1ea34ea2518627
|
CREATing cOmmunity eneRgy Systems
|
European Commission
|
Autoritat Portuària de Barcelona (Port de Barcelona)
|
CORDIS-957815
|
CREATORS enables local initiators to create and operate advanced Community Energy Systems (CES) by supporting technical, financial and social processes. With the sector moving beyond inventor-lead pilots, local CES initiators lack the capacity for high-quality simulation, business modelling and automated operations that are required in communities with a range of vectors, 1000s of mixed members, and balancing/ trading that requires controls in milliseconds. Leading engineering firms Cordeel and COMSA work with specialists in simulation and energy trading (i.LECO), emulation for digital twins (Typhoon HIL), and financing (EnergyPro) to develop services that enable local professionals to apply state of the art energy system technologies. These applications and integrated packages will mature from TRL5-6 to TRL7-8 and eventually be offered as ´CES-as-a-Service´. The services will deliver 60% preparation and operational costs reductions, ensuring 99,95% uptime, 20-35% CAPEX reduction, and up to 40% additional incomes. The results are 5-10% local energy price reduction (below €0,18kWh) in systems covering all vectors, with 10³ - 10⁴ participants. The approach creates 2 fte jobs in each CES, whilst for partners remote services could reach 10% the system turnover, in what is a high growth market. In standardizing simulation and assessment tools in close collaboration with local stakeholders (30 LoS), the BRIDGE initiative and lenders (industry-lead Investor Confidence Protocols), CREATORS significantly advances commercial readiness (CRI3). The applications will be developed in 4 sites (Belgium, Spain, Slovenia, Estonia), and replicated in another 6 (the Netherlands, Bulgaria, France, Spain). The pilots mix vectors, participants and business models, covering in total >2000 households, >500SMEs and >5 industrial sites. Ten more prospective CES will be supported in feasibility studies through a competitive process, which also aims to prepare for commercial market entry.
|
H2020-EU.3.3. / 3.3 Societal Challenges - Energy
| 0business_rnd_innovation
|
gen_481b8e2ba6e9959e8921ee76b8a6b111
|
ADS BPA TASK ORDER 2 PUBLIC WEBSITE DEVELOPMENT AND MAINTENANCE
|
NIH
|
BOOZ ALLEN HAMILTON
|
92023A02592023F00002-0-0-1
|
Not available
|
R and D Contracts
| 0business_rnd_innovation
|
gen_13581869b3d73cdc4dda195fd0fdefb1
|
A simulation platform to predict dose and therapeutic window of immunocytokines
|
NIH
|
APPLIED BIOMATH, LLC
|
1R44AI177133-01
|
Project Summary/Abstract Immunocytokines (ICs) are fusion proteins of an engineered cytokine conjugated to an antibody. These novel molecules are the next generation of cytokine-based immunotherapies with potential applications in a diverse range of diseases such as rheumatoid arthritis (RA), psoriasis, and cancer. ICs are designed to selectively target diseased tissue or specific immune cells with minimal systemic immune activation that typically leads to dose-limiting toxicity in recombinant cytokine therapy. However, it is challenging to design a molecule with high target specificity, predict its pharmacokinetics and identify doses that achieve high efficacy but low toxicity, i.e. the therapeutic window. We are proposing to develop a simulation platform for IC screening that will computationally predict dose and therapeutic window of novel ICs under development. The platform will implement a quantitative systems pharmacology (QSP) model that mechanistically describes the binding of an IC to target and off-target cells and links cytokine receptor occupancy to cellular activation and expansion dynamics. The model will predict in vivo pharmacokinetics (PK) and pharmacodynamics (PD) for an input dose and dosing regimen of a proposed IC. Simulations will report readouts such as cell counts and soluble cytokine levels that are clinically observable biomarkers of efficacy and toxicity. The model will be general enough to simulate pro- and anti-inflammatory ICs. A modular design will allow us to add new cell types and cytokines/receptors as needed to adequately model the crosstalk between the inflammatory and regulatory arms of the immune response. In Phase I of this Fast Track proposal, we will demonstrate the technical feasibility of developing a single mechanistic QSP model structure that captures drug dose- dependent expansion and contraction of four unique IC molecules. By fitting preclinical and clinical data for each molecule, we will establish a robust translational strategy for human dose prediction. In Phase II the platform model will be integrated with and made accessible through Applied BioMath’s Assess™ browser-based interface. With this setup, users can interactively explore the IC design space and use simulations to understand the impact of varying dose, dosing interval, target affinities, cytokine potency and drug half-life on clinical PK/PD. We expect that this interactive tool will foster effective communication within multidisciplinary drug development teams, and help them rationally identify optimal molecular characteristics and dosing strategies for novel ICs. The platform will also allow virtual patient cohort simulations to guide selection criteria for clinical trials. There are currently no effective tools to screen candidate molecules in the IC space. Our proposed computational platform to predict the optimal dose and therapeutic window of novel ICs will accelerate the lengthy and expensive lead candidate selection process, and thus lower the cost of IC development, facilitate clinical trial design, reduce late stage attrition and bring new drugs to the market faster to benefit patient healthcare. Project Narrative Immunocytokines (IC) are a promising class of cytokine-based therapeutics with high efficacy, but achieving an adequate therapeutic window is complicated by potentially high risk of toxicity due to off-target effects. The proposed project will develop a simulation platform to facilitate the prediction of optimal dose, therapeutic window and best dosing strategy for a more efficacious and safer treatment for patients. This simulation platform will help optimize the next generation of ICs developed to treat diseases such as rheumatoid arthritis and cancer by addressing key questions in IC drug development.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_fb6fa03ac62589b5300ba2262dd895c0
|
Multiplexed analysis of secreted proteins from single-cells using high dynamic range nanovials
|
NIH
|
PARTILLION BIOSCIENCE CORPORATION
|
1R43AI179363-01
|
ABSTRACT Cellular secretions make up a significant portion of the proteome, playing a crucial role in governing a range of bodily functions – in particular immunity. Despite their significance, the study at cellular secretions at the single- cell level has been limited due to a lack of accessible technologies. An ideal assay would have single-cell resolution, measure several secreted products, and allow for recovery of cells for further downstream study. No one assay fulfills all of these requirements. The lack of methodologies to identify and interrogate cells which display high levels of secretory capacity has effectively stalled research into these potentially highly potent cells for cell therapies. The most common technique to characterize cell secretion at the single-cell level is the decades old ELISpot technology, however, this technology is limited in the number of secretions that can be measured and cells cannot be sorted based on the results of the assay. Thus, there is a critical need to develop accessible technologies which offer the capability to functionally screen and recover cells in a highly multiplexed secretion format. To address this gap, we will engineer nanovials, cavity-containing hydrogel particles, to create a robust 5-plex assay format capable of measuring five secreted cytokines from single cells, supporting several different workflows such as rare polyfunctional T cell sorting, or other immune cell screening by function. In the first aim of this project, we will develop nanovial formulations compatible with a 5-plex secretion assay by increasing the number of binding sites for secretion capture. We will also identify suitable antibody pairs and modification stoichiometry for IFN-gamma, TNF-alpha, GM-CSF, IL-2, and Granzyme B. In the second aim we will validate the nanovial single-cell assays by comparing the single-cell secretions of HLA-matched PBMCs activated by peptide presentation using both ELISpot and the developed nanovial assays. Successful completion of our aims will address critical gaps in traditional secretion-based profiling of single cells such as ELISpot or intracellular cytokine staining. This multiplexed assay will enable researchers to discriminate and recover highly functional cells which will spur innovation in both fundamental research and therapeutic development. NARRATIVE Cell secretions play a crucial role in many bodily functions, but there are currently no tools available that can measure multiple secretions from single cells and allow the cells to be recovered for further study. This project aims to develop accessible technologies that can measure the secretions of individual cells in a highly multiplexed format, which could lead to a better understanding of how cells function and potentially lead to the development of new cell therapies.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_26086d5ac8bee1ef3702828109e2777b
|
Development of ultra-efficient antibodies for single cell mapping applications
|
NIH
|
EPICYPHER, INC.
|
1R44AI174357-01
|
PROJECT SUMMARY Histone post-translational modifications (PTMs) are some of the most widely studied epigenomic factors, and alterations in histone PTM abundance / distribution have been implicated in numerous disease etiologies. Epigenomic mapping of histone PTMs in limited cell populations or single cells (SCs) would provide the opportunity to study the epigenetic landscape of rare and heterogenous cell populations and be highly enabling for drug discovery research. The recent development of the antibody-mediated genomic mapping approach CUT&Tag (Cleavage Under Targets and Tagmentation) permits the study of select, abundant histone PTMs using very few cells and even SCs. Despite this progress, ultra-low input and SC CUT&Tag assays still present a unique challenge, and have not yet been successfully applied to many challenging targets, such as less abundant histone PTMs. Indeed, to maximize data yield per cell, ultra-low input and SC CUT&Tag assays require antibodies to exhibit high on-target epitope binding with minimal off-target binding, which most commercial antibodies do not offer. We envision a new class of “SC-grade” antibodies that deliver ultra-efficient histone PTM binding for dramatically increased CUT&Tag assay sensitivity, improving reliability and providing access to new targets that are currently intractable. Here, EpiCypher will leverage a novel antibody development pipeline to generate ultra-efficient, “SC-grade” antibodies to unlock the potential of genomic mapping technology for next- generation ultra-low input / SC applications. Unlike traditional antibody development pipelines that use histone peptides for screening, a central innovation of our strategy is the implementation of recombinant modified designer nucleosome technology during antibody development. In Phase I equivalent studies, we used our novel approach to select and validate ultra-efficient antibodies for two key histone PTM targets (H3K4me1 and H3K4me3), generating antibodies that exhibit a >5-10x increase in nucleosome capture efficiency vs. current best-in-class antibodies. Importantly, these ultra-efficient antibodies generated significantly greater signal-to- noise in genomic mapping assays that employ low cell inputs, demonstrating strong proof-of-concept for our approach. In Phase II, we will leverage this validated antibody development pipeline to develop a suite of ultra- efficient antibodies and use these reagents to develop low input and SC CUT&Tag assays for breakthrough immunology research. Toward this goal, we will first develop and screen antibodies for high-value histone PTM targets (Aim 1). We will then scale up production and rigorously validate antibody lots in CUT&Tag assays using both low input and SC workflows (Aim 2). Finally, we will test the application of our next-generation ultra-efficient antibodies to enable cutting-edge immunological research and provide our antibodies and validated protocols to leading epigenetics laboratories for beta testing (Aim 3). This research project will result in the development of a new class of histone PTM antibodies that will be used to increase the utility of CUT&Tag assays for breakthrough chromatin research and drug discovery. PROJECT NARRATIVE Histone post-translational modifications (PTMs) are some of the most widely studied epigenomic factors, and alterations in histone PTM abundance and distribution have been implicated in numerous disease etiologies. However, efforts to map histone PTMs in limited samples and single cells, such as rare primary immune cells and clinical samples, have been hindered by the lack of high-quality antibodies. To meet this need, EpiCypher is developing a novel antibody development pipeline to create ultra-efficiency antibodies that enable low and single cell genomic mapping assays.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_3d54979d3e8ef83289cea97b69251448
|
Tumor Monorail Device for Serial Glioblastoma Biopsy
|
NIH
|
EXVADE BIOSCIENCE, INC.
|
1R44CA285039-01
|
Project Summary/Abstract Glioblastoma (GBM) is one of the most common and deadliest form of malignant brain tumors, with median patient survival of 12-15 months and five-year survival of less than 5%. The current standard of therapy for GBM comprises surgical resection then radiation and chemotherapy. However, due to the heterogeneity and invasive nature of GBM tumor cells there is a high rate (~80%) of tumor recurrence, leading to dismal survival rates that have not changed significantly in over 50 years. One of the primary hurdles to improving these out- comes is the lack of reliable and accurate means to monitor tumor progression and treatment response. The current standard methods of tumor monitoring, direct tissue biopsy and external imaging, are not able to safely provide accurate, focal, longitudinal information about the tumor progression and treatment response that would allow clinicians to modify treatment regimen to improve survival outcomes. Here we propose the Tumor Monorail as a platform that allows direct, serial access to tumor material, providing critical information about tumors in real time that will help clinicians improve active treatment management and patient survival. The Tumor Monorail is a Breakthrough Designated device and has been the subject of multiple FDA pre-sub- mission meetings and extensive verification and biocompatibility testing. By leveraging design and material se- lections with a long history of safe clinical use, the Tumor Monorail can safely provide access to this typically inaccessible tumor in an outpatient setting. This will provide clinicians with an unprecedented amount of infor- mation about tumor genetics and treatment response in real time that is critically important to improving out- comes for the treatment of GBM. The potential impact of this paradigm shifting diagnostic tool is wide ranging, including enhancing the efficacy of current standard of care and novel treatment regimens, increasing clinical trial efficiency by accelerating patient placement and data collection, removing uncertainty about treatment effi- cacy and tumor progression inherent in imaging, and more. The aims of this proposal are focused on optimization and clinical translation of the Tumor Monorail as a plat- form for longitudinal GBM sampling. In the Phase 1 portion of the proposal we will first optimize the sampling ability and cellular migration in the device and perform multiple pre-clinical verification tests that will improve usability and ease regulatory approval. In the Phase II portion we will validate the device efficacy in concert with standard of care treatment in a rodent model and perform more FDA requested pre-clinical testing that will confirm long term explantability, clinical usability, and preparation of the device for rapid clinical translation. These activities will ensure that the Tumor Monorail is well positioned for submission of an Investigational De- vice Exemption (IDE), clinical translation, and rapid adoption to provide a new treatment path for GBM focused on active disease management and individually targeted, responsive treatment that would allow clinicians to tailor interventions in real time, increasing patient outcomes that have been stagnant for decades. Project Narrative Glioblastoma Multiforme (GBM) is a highly aggressive form of brain cancer with a fatality rate close to 100% despite aggressive therapies, primarily because the invasive nature and inaccessibility of the tumors makes recurrence after treatment very common and treatment efficacy hard to assess. We have developed a system that can provide serial direct tissue biopsy of the tumor, allowing for collection of data about the tumor genetic profile and treatment efficacy that will allow clinicians to make more informed decisions about treatment course and accelerate entrance into suitable clinical trials. This information will empower clinicians by giving them access to an unprecedented level of information about tumor response to treatment in real time, allowing them to enhance the effectiveness of current treatments, increase the efficiency of clinical trials, and finally improve GBM outcomes that have not changed in decades.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_1c5e0423159384e7b7966fbc83f8c98b
|
ADDITIVE MANUFACTURING OF PDMS MICROFLUIDICS
|
NIH
|
PHASE, INC.
|
2R44TR003968-02
|
Development of new therapeutics often fails in human clinical trials due to the biological differences between humans and animal models and the inability of current in vitro models to accurately recapitulate the in vivo state. As such, in vitro microfluidic (MF) models have seen significant growth and become a key tool for understanding biological systems, and for testing and development of new therapeutics. Innovation in microfluidics, however, is limited by materials and manufacturing challenges associated with conventional processes such as soft lithography, injection molding, and mechanical milling. Additive manufacturing (AM), also referred to as 3D printing, has been heralded as the solution to these manufacturing challenges and AM additionally offers broad design freedom not accessible via conventional manufacturing. However, AM faces a critical hurdle: the limited ability to 3D print conventional (thermally-curable) polydimethylsiloxane (PDMS), the most widely established R&D microfluidic material. Despite the potential manufacturing and design benefits, AM has not been broadly adopted for MF production due in large part to the potential material risks. Of the commercially available AM processes and those being researched, none offer a clear path to commercial 3D printing of conventional PDMS MF devices. Our hypothesis is: combining the knowledge-base and familiarity of conventional PDMS with our 3D PDMS process will fundamentally change the way microfluidics are fabricated and unlock the design freedom of additive manufacturing for the MF community, which will lead to significant advancements of in vitro MF models. Building upon our successful Phase I effort — during which we demonstrated the ability of our patent-pending 3D PDMS process to 3D print MF devices from conventional PDMS — this Phase II effort focuses on developing a pilot-scale commercial 3D PDMS system and using the 3D PDMS process to fabricate cutting edge in vitro blood-brain-barrier models for testing by our collaborators at Virginia Tech. They recently developed a MF BBB model containing a nanofiber basement membrane mimic which demonstrates a superior ability to recapitulate the in vivo BBB architecture. In Phase II, the team will optimize the architecture of the nanomembranes and then design and demonstrate a commercially producible 3D PDMS MF nanomembrane BBB model with integrated electrodes. We will also collaborate with the Nadkarni group at Harvard MGH to characterize the PDMS curing kinetics in 3D PDMS printing using laser speckle rheology. Aim 1: Operational Pilot-Scale 3D PDMS System. The objective of this aim is to design and a build pilot-scale 3D PDMS system. Milestone 1A: 3D PDMS Simulation & Model Accurately Predict Curing within +/-10%; Milestone 1A: 3D PDMS Simulation Model Accurately Predicts Curing within +/-10%; Milestone 1B: 3D PDMS unit achieves 200 mm3/hr build rate for MF device. Aim 2: 3D Printed Nanofiber Blood-Brain-Barrier Model. The objective of this aim is to 3D print a highly reproducible BBB model which incorporates a nanofiber membrane and integrated TEER electrodes. Milestone 2A: Transport master curves for nanofiber membranes developed; Milestone 2B: Optimized nanofiber BBB model demonstrated by a 20% increase in TEER values for a co- culture sample as compared to a monoculture sample. Project Summary/Abstract Narrative Microfluidics (MF) are the test tubes of the digital age and play a vital role in drug discovery, biotechnology, lab- and organs-on-a-chip, personalized point-of-care diagnostics and treatment, disease research, and more. Phase, Inc. is developing a new 3D printing technology to create PDMS microfluidics that believe will fundamentally change the way PDMS microfluidics are fabricated and unlock the design freedom of additive manufacturing for the MF community, which will lead to significant advancements of in vitro MF models. This new 3D printing technology will allow researchers to quickly design and create microfluidic devices in a matter of hours – as opposed the weeks it now takes. This will enable researchers to more quickly test drugs to treat illness and decrease the time needed for new medicines to reach the market and, in turn, patients. Narrative
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_99f597ab514511cac67f319c5dfa68af
|
NIAID Division of AIDS (DAIDS) Chemotherapeutic Agents Repository
|
NIH
|
FISHER BIOSERVICES, INC.
|
75N93021D00012-0-759302400001-1
|
Not available
|
R and D Contracts
| 0business_rnd_innovation
|
gen_b40741736f54095e4adca01b75ae4117
|
Development of CA-IL-12 for Triple Negative Breast Cancer
|
NIH
|
CYTONUS THERAPEUTICS, INC.
|
5R44CA250887-03
|
Most cancer patients die as a result of metastatic disease and our inability to effectively deliver therapeutic drugs into the anatomical niches where cancer cells thrive. Thus, there is a major unmet need to develop therapeutic strategies that effectively target cancer cells in the local tumor microenvironment (TME) while minimizing peripheral toxicity. Cytonus Therapeutics and UCSD Moores Cancer Center has co-developed a highly innovative first-in-class drug transporter platform (CargocytesTM) that is a safe and effective means to deliver therapeutic drugs to treat primary and secondary tumors. Cargocytes possess several unique features that we leverage for precision delivery of cancer therapeutics to patients with metastatic disease. First, Cargocytes possess innate tumor trophic properties and are engineered with additional homing controls that allow for precise, predictable, and safe delivery of therapeutic cargo to the TME. Moreover, because they lack a rigid nucleus, they clear critical FDA barriers to safety due to their inability to transfer or inappropriately express genomic DNA. In addition, they are smaller and more malleable than nucleated carriers and better able to penetrate deep within tumor tissue and metastatic foci. Furthermore, they retain all biosynthetic machinery and can express biological cargo within the TME. While Cargocytes can deliver a wide range of therapeutic cargoes, they are ideally suited for locally delivering potent immune activating agents, such as IL-12, into the immunologically “cold” TME. Our phase I proof-of-concept work shows that Cargocytes precisely deliver IL-12 into the TME, deeply penetrating and interdigitating within metastatic foci when delivered intratumorally or systemically and resulting in a dramatic reduction in metastatic burden that can be measured within 24 hours. While this was demonstrated using Cargocytes that secrete IL-12 (CA-IL-12), we have since focused on development of Cargocytes for intravenous delivery, a more desirable administration route for clinical development and treatment of systemic metastatic disease. Therefore, Phase II work will evaluate the potential of intravenously administered Cargocytes to deliver secreted (CA-IL-12) or surface contained (CA-scIL-12) to breast cancers that have metastasized to lungs or liver. Our hypothesis is that Cargocytes will home to metastases, deliver IL-12 deep within disease foci, and break immune tolerance when used in combination with ICB. This will lead to i) local and systemic antitumor immunity, ii) a reduction in metastatic burden, iii) improved tumor-free and overall survival, and iv) durable antitumor immunity. Three specific aims are outlined to test this hypothesis. Aim 1 will determine the abilities of peripherally administered CA-scIL-12 and CA-IL-12 to locally deliver IL-12 to primary and secondary tumors and to reprogram innate and adaptive anti-tumor immune responses. Aim 2 will then evaluate the ability of our lead CA-IL-12 medicine selected in aim 1 (CA-IL-12L) in combination with PD-1 antibody in the adjuvant setting to effectively treat ICB refractory tumors and generate systemic antitumor and antimetastatic immunity. Aim 3 will test the therapeutic efficacy of CA-IL-12L and ICB in a robust preclinical model of spontaneous breast oncogenesis that preserves tumor heterogeneity. Narrative. Cancer is a systemic disease and conventional treatment strategies that are administered systemically, ultimately fail due to an inability to achieve antitumor efficacy at tolerable doses for the patient. Cytonus has developed a first-in-class, precision delivery platform, called CargocytesTM, that is a safe and effective means to target therapeutic drugs to primary and secondary tumors. In this phase II study, we will evaluate the therapeutic efficacy of systemically-delivered, locally-active, membrane-tethered or secreted IL-12 to induce durable systemic antitumor and antimetastatic immunity.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_aa4c0a07a6263c6216b2147abf7dc802
|
Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
|
NIH
|
LUMINARY THERAPEUTICS, INC.
|
1R44CA278021-01A1
|
ABSTRACT Since the first FDA approval of chimeric antigen receptor (CAR) T cell therapy in 2017, the use of engineered T cells expressing specific CARs to treat cancer has generated durable cures for many patients. Nevertheless, a significant subset of patients with B cell malignancies relapse following treatment due to lack of CAR T cell persistence and the ability of cancer cells to change with time and evade therapeutic interventions. Autologous T cell therapies also carry significant timeline and cost burdens, making widespread adoption difficult. In this application, we propose a novel allogeneic CAR T cell therapy aimed at improving outcomes for patients with mantle cell lymphoma (MCL) by overcoming deficiencies present in current generation CD19 targeted therapeutics. B cell activating factor (BAFF) provides critical survival signals to both normal and neoplastic B cells through a family of receptors (BAFF receptor, TACI, and BCMA) thus mitigating potential for antigen escape. BAFF and its receptors have remained underexplored in the context of B cell malignancies where strategies have relied overwhelmingly on pan B cell antigens such as CD19 and CD20. Since BAFF binds its receptors with moderate affinity, we believe this will increase the ability of these cells to form memory populations and engage in serial killing. We will leverage this ligand-based CAR design in an allogeneic gamma delta (γδ) T cell platform, as γδ T cells have been shown to have high replicative properties in vitro and do not mediate graft versus host disease in new hosts. We have produced preliminary data that confirms our ability to use the non- viral TcBuster DNA transposon system to generate T cells with BAFF-CAR expression. The overall objective of this proposal is to further develop and evaluate our γδ BAFF-CAR T cell therapy for the treatment of MCL in IND enabling studies. In doing so, our allogeneic BAFF-CAR T cell therapy supports an urgently needed shift in therapeutic development toward new tumor antigens that protect against antigen escape while reducing the manufacturing burden associated with cellular therapies through use of a readily available cell source. PROJECT NARRATIVE This proposal describes a novel allogeneic chimeric antigen receptor (CAR) T cell therapy that aims to improve outcomes for patients with mantle cell lymphoma. Our approach improves upon current immunotherapies by engineering T cells in a unique way to express a novel CAR against multiple underexplored targets in an allogenic platform. We expect immunotherapeutic delivery of these modified T cells will reduce disease recurrence by preventing antigen escape, improving persistence, and decreasing manufacturing burden.
|
SBIR/STTR
| 0business_rnd_innovation
|
gen_05250a55266f355c98a73d758b446c27
|
REBOND FEDER loan fund Lower Normandy
|
Kohesio
|
BPIFRANCE FINANCEMENT
|
https://linkedopendata.eu/entity/Q3673261
|
COVID-19 is a major socio-economic shock and uncertainties about developments over the coming months are high. The economic and financial consequences generate financing failures due in particular to the systemic nature of the shock (stoppage of business activities, disruption of supply chains, inducing a surge in the volume of cash flow needs over a concentrated period and an uncertain duration even as the financing market, particularly banking, faces the financial and economic consequences of the crisis (increased market volatility, uncertain economic outlook, costs of risk and increased liquidity, etc.). failures compromise the survival of businesses and the objectives of competitiveness and economic growth pursued by the FEDER Operational Programs. The operation presented will mobilize FEDER within the framework of a “FEDER Rebound Loan Fund 2014-2020”, a financial tool to aid economic development, for the benefit of small and medium-sized businesses encountering a cash flow need linked to cyclical difficulty or a situation of temporary fragility linked in particular to the measures taken within the framework. of COVID 19. The fund will intervene in the form of a zero-interest loan - without guarantee requirements and over a period of 7 years, to support projects to strengthen the financial structure and mainly cash flow needs linked to the economic situation, the increase in the need for working capital.
|
Smarter Europe / Competitiveness of SMEs / Advanced support services for SMEs and groups of SMEs (including management, marketing and design services)
| 0business_rnd_innovation
|
gen_a33452fdd1c36c2c75bd9b15021688bd
|
FEDER - ISPA-E - REACT PROJECT
|
Kohesio
|
ISPA ENTREPRISES
|
https://linkedopendata.eu/entity/Q3680231
|
The unique properties of plastics explain the extent of their use in food packaging. They are light, which ensures reduced transport costs and lower CO2 emissions. They are transparent and custom trainable, which offers unparalleled marketing opportunities. But above all, through their barrier effect, they protect foods from oxygen and water which can quickly alter their quality or even make them dangerous for consumption. The use of plastic in packaging has thus largely contributed to reducing food waste, to curbing health problems relating to the food trade and to fighting against famine and malnutrition. The packaging industry, a victim of its success, consumes nearly 40% of plastic materials, the majority of which is used for food packaging. In France, each year, more than a million tonnes of plastic materials are used and placed on the market for household and food packaging. Unfortunately, a large part of these plastics are only used for their initial function (e.g. ham trays) and are neither reused nor recycled. Thus, 44% of French plastic waste is incinerated, and 34% is buried in landfills. Only 22% are recycled, mainly PET bottles. The low recycling rate of these consumer products is linked to the fact that only plastics isolated from others are recyclable. For example, a few percent by mass of PP in a volume of PET makes it impossible to recycle the latter. This is why efficient sorting of household plastics is essential to ensure the value chain of these materials. However, the vast majority of plastic packaging consists of co-extruded or laminated multilayers using different types of resin, each providing one or more specific properties. Alongside recycling, a second alternative to the treatment of plastic waste is the use of biodegradable, or even compostable, packaging for short-life applications, in the concept of Circular Economy and with the opportunity to overcome the difficulty relating to the multi-material nature of packaging. multilayers.To date, there is no high-performance recyclable or compostable food packaging. It is therefore urgent, in the interests of sustainable development, to design eco-responsible food packaging materials that are recyclable or compostable, or even both at the same time. The Normandy region, with the strong presence of academic and industrial players covering the entire value chain concerned (formulation and compounding of new materials, implementation of manufactured products, recycling and/or composting), appears ideally placed to develop this new job-creating sector, while improving eco-design of products and sustainable management of raw materials. Current societal challenges, which are the scarcity of resources and the end-of-life management of materials, must indeed make the development of materials from renewable resources a priority research axis at the heart of territorial challenges for transitions and sustainable development. The REACT project brings together a packaging manufacturer (B+K), a technology supplier (Polytechs), three research laboratories (UniRouen PBS), UniLaSalle UTA and ISPA), a technical center (IPC) and a CRT (Praxens). The project will lead to the creation of 10 direct jobs at the end of the project and several dozen over the next 3/5 years. REACT will be a pilot project for the creation of a regional sector intended to be duplicated on a national/European scale. Duplicating the Normandy sector on a national scale could lead to a reduction in CO2 emissions of around 1.7 Mt per year.
|
Smarter Europe / Research and innovation / Research and innovation activities in private research centres including networking
| 0business_rnd_innovation
|
gen_92b673fd5c5f14733dc5859a283f50d7
|
FEDER - PEG - AEROTEX PROJECT
|
Kohesio
|
P.E.G.
|
https://linkedopendata.eu/entity/Q3681979
|
The Aérotex project aims to revolutionize the field of thermal insulation for the technical clothing and building insulation sectors by developing new environmentally friendly materials with high thermal insulation performance, light, thin and flexible. To achieve this objective, the partnership will combine innovative technologies, such as silica airgel and Fibroline dry impregnation technology, with the know-how of leading insulation players and the expertise of university laboratories in the Auvergne-Rhône-Alpes and Normandy regions. The Aérotex project consortium is made up of 6 partners: PEG, Balsan, Millet, Fibroline, Enersens and Cethil. PEG is positioning itself in the project as both an expert supplier of raw materials (Polyester fiber wadding) as well as an end-user for a highly strategic field, building insulation. Integrating a collaborative innovation project will allow them to access all the technological expertise (ecological impregnation technology and Airgel insulating material) and scientific expertise (Characterization and modeling of insulators by the Cethil laboratory) to make this development a success in the Normandy region. During the project, insulation materials will be developed by optimizing fiber wadding and innovative impregnation technology. The performance of the impregnated Airgel will be analyzed and optimized to achieve the desired performance. The development of the prototypes will be done with an important point which is the resistance of the Airgel during handling and washing. Ultimately, 3 prototypes will be developed: a sleeping bag, a technical jacket and insulation for the building.
|
Smarter Europe / Research and innovation / Research and innovation activities in private research centres including networking
| 0business_rnd_innovation
|
gen_a0b46adade9510aa92ca49e0d1e73ef2
|
HN0004952 - LINEN SAINT MARTIN - OLCO: COMPOSITE LINEN OPTIMIZATION
|
Kohesio
|
LA LINIERE DE SAINT MARTIN
|
https://linkedopendata.eu/entity/Q3680953
|
Aware of the potential of linen fiber due to its properties, LSM has developed, with the skills of Mr. VANFLETEREN François, new products for composite applications. Light, ecological and with a strength close to that of fiberglass, flax fiber - transformed into linen sail - can in fact be the subject of multiple applications (boat hulls, skis, tennis rackets, bicycle frames, etc.) and thus enjoys a growing reputation in different sectors of industry such as automobiles, aeronautics and leisure. Thus, these new markets constitute very strong development potential for flax fiber as reinforcing fiber. Consolidation and gaining market share in composites require R&D work, particularly to optimize the technical and mechanical properties of Linen ribbons. In the OLCO project, LSM, preparer of flax for composite, joins the AGRI'TERR laboratory of the Institut Polytechnique LaSalle Beauvais-Esitpa in partnership to jointly carry out this research program.
|
Smarter Europe / Research and innovation / Research and innovation infrastructure, processes, technology transfer and cooperation in enterprises focusing on the low carbon economy and on resilience to climate change
| 0business_rnd_innovation
|
gen_7fe784a840783423636d081be89c327f
|
FEDER - 6NAPSE - MIMME PROJECT
|
Kohesio
|
6NAPSE
|
https://linkedopendata.eu/entity/Q3681475
|
- The reliability of on-board systems is a major issue for manufacturers in different sectors such as aerospace, aeronautics, automobiles, railways - The testing conditions imposed by manufacturers are increasingly strict - The demand from large groups is oriented towards: - The need to carry out innovative tests in vibration, thermal, fluid mechanics and materials analysis - A single point of contact for carrying out their research and development tests - For their part, SMEs insist on the need to simplify protocols Controlling product reliability will require in the near future: - A multi-physics approach (materials, mechanics, thermal, electrical) - A close correlation between digital and experimental approach - Testing means adapted to new customer requirements
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_1d5909c7f655498b0a313502acc4e4ee
|
FEDER - V@SY - PEPSY PROJECT
|
Kohesio
|
VISIO ACTIVITES SPORTIVES INTERACTIVES
|
https://linkedopendata.eu/entity/Q3673404
|
The PEPSY V@SI project is part of the field of specialization “Innovations in Biomedical Sciences and Technologies but also in the field of “Digital & Society”, mobile services sub-field of the research and innovation strategy based on intelligent specialization (RIS3) of the Lower Normandy region. Thanks to the expertise provided by the 2 laboratories in the field of schizophrenia for one (ISTS, UMR 6301) and in the field of APA for the other (COMETE, U), this project aims to develop an Adapted Physical Activity (APA) offer for patients presenting a schizophrenic disorder, a chronic, frequent pathology (1%), causing disability (80% of patients), a high sedentary lifestyle and severe co-morbidities (obesity, diabetes, cardiac pathologies). APA has already shown its effectiveness in reducing co-morbidities, social adaptation and quality of life in the general population. The major innovation of the program lies in the development of a complete offer covering the entire value chain: medical prescription, construction and individualized implementation of remote support (tele-support) through Adapted Physical Activity, deployment of an interactive technological platform integrating a video-conferencing system and a physiological data monitoring system (sensors). Tele-support developed by V@si is a promising and innovative way to facilitate patients' access to physical exercise. Indeed, physical capacities are lower in schizophrenic patients who are little motivated to go to traditional fitness centers. In parallel with this, the main objective of BodyCap within this research program is to provide and/or develop innovative solutions for monitoring heart rate and activity responding to all the constraints inherent in monitoring the target populations of this type of program; namely: - reliable and precise measurement of these parameters, - monitoring and feedback of information in real time, via a dedicated platform, - post-processing allowing, if necessary, to highlight the variability of the heart rate, - level of performance ensuring good acceptability on the part of the user: o confidentiality of data, o lifespan, o storage capacity, o transmission distance, o speed of data unloading. - Preserve user comfort: o miniaturization of the device, o optimization of the design and materials used. The ob'do Contact Agile company is participating in the project by focusing on the integration of the video-conferencing and physiological data monitoring system used by participants during remote coaching sessions. We will call this system the V@siBox. The action of ob'do Contact Agile is initially to set up prototypes of the V@siBox at the start of the project in order to start the research program. The V@si Box will have the function of connecting commercial sensors (example: BodyCap and ZephyrMonitoring). Secondly, ob'do Contact Agile will offer an industrializable version of the V@siBox thanks to feedback from the field. The ob'do Contact Agile team will be heavily involved in the first part of the program by creating prototypes. Its activity will continue with the maintenance and improvement of V@siBoxes and the preparation of their industrialization.
|
Smarter Europe / Research and innovation / Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
| 0business_rnd_innovation
|
gen_8f3b1f51cc12256c9de2fc5c5d8e6379
|
FEDER - NXP - PF CNES PROJECT
|
Kohesio
|
NXP SEMICONDUCTORS FRANCE
|
https://linkedopendata.eu/entity/Q3680132
|
Treating differently is a public health imperative in a context of population aging, medical desertification and increased patient demands. It is also an economic imperative which particularly affects France, whose health expenditure is today growing more strongly than GDP. The French health system, which was built on acute medicine and around the hospital, will have to reorient itself towards the management of a care pathway within which the hospital will certainly be an important step, but which will have to be more part of a collaboration with actors outside the hospital. In this logic, e-health has its place and holds promise for facing challenges and preserving the fundamentals of the health system while increasing its added value for professionals and patients alike. The development of digital solutions will make it possible to place the patient at the center of the care ecosystem with a set of medical and paramedical professionals gravitating around them. Building on this observation, NXP, an internationally renowned manufacturer in the IOT and secure transactions market, ELITT expert in the interoperability and security of card payment data, Pertimm, an SME with 20 years of experience in artificial intelligence and GREYC, a laboratory whose research work in algorithms and biometrics, have joined forces to develop an e-health digital trust platform (PF CNES) in the Caen area. This large-scale industrial project is awaited by regional economic players in the world of health, as well as organizations working to bring together the e-health sector in Normandy. This PF CNES platform is intended to be collaborative and unifying, in order to facilitate the rapid and sustainable adoption of e-health products and services. It aims to: Promote Innovation on an industrial scale by providing partners with industrial technological building blocks and support in certification processes and relations with regulatory authorities; Guarantee a level of Security and Integrity of health data in accordance with the requirements of health regulatory authorities; Facilitate the experimentation and deployment of products and services at the national and international level thanks to their interoperability. The challenge of this platform is certainly economic, but above all it is about bringing about societal innovation. Indeed, digital technologies represent a real opportunity to improve the quality of care for the patient and to improve the daily lives of professionals thanks to the organizational changes they allow. The economic challenge is to improve the efficiency of the health system and health spending and to create an e-health industrial sector which respects the standards/requirements of the regulatory authorities (security, interoperability, integrity), which innovates and which trains.
|
Smarter Europe / Research and innovation / Technology transfer and university-enterprise cooperation primarily benefiting SMEs
| 0business_rnd_innovation
|
gen_32a525737d53bcfb30016b8a6c5b69f5
|
FEDER - SEML Innovation Development Bio Materials - Compoline 2 Project
|
Kohesio
|
SEML INNOVATION DEVELOPPEMENT BIO MATERIAUX
|
https://linkedopendata.eu/entity/Q3673436
|
Conventional wood panels are produced from wood flour or wood fibers bonded with a thermosetting resin, which is accused of emitting volatile organic compounds (VOCs) such as formaldehyde. These formaldehyde emissions are, today, heavily regulated by various European directives. Waste from the manufacturing and machining of MDF panels as well as that from the end of the life of furniture is not currently recycled and is either sent to landfill or crushed and put into a steam boiler. The woodworking profession is concerned about this and is looking for more environmentally friendly solutions. To remain competitive and face competition from countries with low labor costs, furniture and interior design companies must be innovative and respond to the needs of the market which requires greater customization of products and constant evolution of design. The Compo'line project financially supported by Europe through the objectives of axis 1 of the ERDF "develop the regional innovation potential" of measure 1.2 “making research a priority instrument for the competitiveness of the Lower Normandy economy” and sub-measure 12.2. "supporting partnership research projects between research centers and companies, presenting opportunities in terms of market" by the, the State (DIRECCTE) and the Lower Normandy Region over the years 2010 to 2013, made it possible to develop a 100% bio-sourced thermoformable hybrid wood for furniture and interior design whose commercial name is Selun®. For the wood sector, the project aims upstream to recycle waste from the wood industry in high value-added applications and downstream to modernize furniture manufacturing processes to adapt them to the requirements of the current market and make them more competitive. It aims to innovate in terms of design in order to offer a new furniture offering. Finally, it allows the wood industry to offer recyclable furniture and interior fittings. The arrival on the market of Selun® should make it possible to give new impetus to the regional wood industry, hard hit by company relocations and the consequences of the 1999 storm. This project has been supported since the beginning by the PROFESSIONBOIS association (Interprofessional Association Forêt Bois de Basse Normandie) which brings together the different players in the wood industry. lower-Norman (foresters, sawyers, cabinetmakers, architects), CODIFAB (professional committee for the development of the French furniture and wood industries) and VIA (Valorization of Innovation in Furniture, whose mission is to promote creation and innovation in the sector of furnishing the domestic, professional or urban living environment). The Architect@work trade show in October 2013 where the Selun® was presented for the first time to professionals (architects, specifiers, major accounts) and the numerous contacts such as Beneteau, Bouygues have made it possible to verify the excellent reception of the material which foreshadows a very good entry into the luxury and boating construction materials (2nd work) market. An in-depth European and global market study combined with a business plan are essential for the development of an industrial and commercial development strategy for Selun® as well as its production method and logistics.
|
Smarter Europe / Research and innovation / Research and innovation activities in private research centres including networking
| 0business_rnd_innovation
|
gen_462a243850877703aba484d694371398
|
2019 - Support for artisans and traders in the use of digital technology
|
Kohesio
|
COMMUNAUTE DE COMMUNES DE VILLEDIEU INTERCOM
|
https://linkedopendata.eu/entity/Q3680195
|
The Normandy Region set up an FEDER (European Regional Development Fund) system in April 2018 which is aimed at EPCIs with an approach to raising digital awareness among artisans/traders. This system falls under measures 1.4 of the Orne/Manche/Calvados Operational Program. The digital transition of craftsmen-traders is a major issue for the Region, both to respond to its economic development strategy and to ensure the sustainability of crafts. and local businesses which largely contribute to social ties in the region's towns and medium-sized towns. To this end, the Region wishes to strengthen the EPCIRégion duo to support artisan-retailers in their digital transformation. Indeed, the benefits of digital tools and services for these players are major in terms of productivity and efficiency: time saving, cost reduction, simplification of management, optimization of organization, improvement of the quality of products and services, visibility to the public. This aid, awarded in the form of a grant, aims to support EPCIs in awareness-raising and support actions for artisan-traders for the appropriation of digital tools in their professional practices: - Global and individual diagnosis of the use of digital tools and services by artisans/traders - Conducting awareness-raising workshops/sharing digital experiences - Individual or collective support These actions can be carried out by EPCI staff and/or by external service providers. The amount of FEDER aid amounts to 50% of expenses and the amount of the grant granted cannot be less than €20,000 (i.e. a minimum amount of eligible expenses of €40,000). The maximum rate of public aid received on the project cannot exceed 80%. It appears today that Villedieu Intercom has initiated this type of approach with craftsmen and traders. As a result, Villedieu Intercom is approaching the Normandy Region as part of this system.
|
Smarter Europe / Competitiveness of SMEs / Advanced support services for SMEs and groups of SMEs (including management, marketing and design services)
| 0business_rnd_innovation
|
gen_5066f1cbfb9f5058a3bdfd18bbe207c4
|
FEDER - DEDIENNE MULTIPLASTURGY GROUP - PROJET THESIS
|
Kohesio
|
DEDIENNE MULTIPLASTURGY GOUP
|
https://linkedopendata.eu/entity/Q3680515
|
The aeronautics sector is constantly looking for solutions to improve performance and limit fuel consumption. In this sense, a technological breakthrough in terms of energy architecture is currently being studied. The objective is to eliminate the drawing of high temperature and high pressure air from the engines and to replace it with the generation of electrical energy. This change in architecture aims to improve the overall energy balance of the aircraft. This change in architecture involves reviewing certain aircraft systems which currently operate using high temperature and high pressure air.
|
Smarter Europe / Research and innovation / Research and innovation infrastructure, processes, technology transfer and cooperation in enterprises focusing on the low carbon economy and on resilience to climate change
| 0business_rnd_innovation
|
gen_18d989059176c18abbe9b5b58986a284
|
CREACOOP 14 - Plan d'actions 2019 - FEDER
|
Kohesio
|
CREA COOP 14
|
https://linkedopendata.eu/entity/Q3680208
|
Support for project leaders aiming to create their own job.
|
Smarter Europe / Competitiveness of SMEs / Advanced support services for SMEs and groups of SMEs (including management, marketing and design services)
| 0business_rnd_innovation
|
gen_a95ff2c4e9fb01832f2909f28df7f415
|
Chief scientific officer's post
|
Arcadia Fundation
|
John Muir Trust
|
360G-ArcadiaFund-2606
|
To provide advice to the trust and its partners on scientific aspects of wild land conservation and biodiversity management.
|
On-site conservation / Strategic
| 1fellowships_scholarships
|
gen_05b35c1fb6e46941741628c33a1174cf
|
Post-doctoral fellowships
|
Arcadia Fundation
|
UCLA Foundation
|
360G-ArcadiaFund-5026
|
Towards supporting post-doctoral researchers in the Center for Early Global Studies at UCLA
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_4c8a014a2ece5e0022b3716afb267637
|
Graduate and post-graduate bursaries
|
Arcadia Fundation
|
African Institute for Mathematical Sciences
|
360G-ArcadiaFund-2524
|
To support female graduates attending the institute and provide half-bursaries for them to pursue master's and PhD programmes in South Africa.
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_f335e3280d95abd50c3e75cb3c758812
|
Miriam Rothschild Travel Bursary Programme and Scholarships Programme
|
Arcadia Fundation
|
University of Cambridge
|
360G-ArcadiaFund-2459
|
To enable students from biodiversity-rich, cash-poor countries to participate in the Student Conference on Conservation Science, and to provide scholarships to PhD students in the Department of Zoology.
|
Leadership / Strategic
| 1fellowships_scholarships
|
gen_540248f46e2ddef57e34376bd4874b59
|
Cambridge Conservation Initiative: Masters in Conservation Leadership
|
Arcadia Fundation
|
Masters in Conservation Leadership - University of Cambridge
|
360G-ArcadiaFund-3737
|
To enable students from biodiversity-rich, cash-poor countries to participate in the Cambridge Masters in Conservation Leadership.
|
Leadership / Strategic
| 1fellowships_scholarships
|
gen_7700a69d3192ae2c69931901554860f3
|
Scholars at Risk
|
Arcadia Fundation
|
Harvard University
|
360G-ArcadiaFund-1293
|
To give fellowships to scholars facing persecution in their home countries.
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_441483bfc33ec47dded188a1e746bf14
|
Endowment fund for fellows
|
Arcadia Fundation
|
Center for Jewish History
|
360G-ArcadiaFund-5038
|
To establish an endowment fund to provide annual fellowships for scholars working at the Center for Jewish History and with the collections of the Center and its partners
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_0e89fc6cd74cc4aca4c2408b86cfde82
|
College fellows fund
|
Arcadia Fundation
|
Harvard University
|
360G-ArcadiaFund-3161
|
To support Harvard College Fellows Program
|
Other / Strategic
| 1fellowships_scholarships
|
gen_77f37e41200bf5e5411c4676db0ee066
|
Visiting fellowship
|
Arcadia Fundation
|
Reuters Institute for the Study of Journalism
|
360G-ArcadiaFund-2582
|
To support visiting fellow Dominic Lawson.
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_bb04e71b5be323d8a90465924cc9b2dc
|
To establish the Scott Waugh Fund for Medieval History, and endowment for the History Department.
|
Arcadia Fundation
|
University of California Los Angeles
|
360G-ArcadiaFund-4177
|
To support graduate students, to bring distinguished visiting scholars to UCLA to give lectures and teach courses, to underwrite conferences and workshops, and for other purposes that the chair of the UCLA History Department determines to be beneficial to the vitality of the field of medieval history at UCLA.
|
Discretionary / Discretionary
| 1fellowships_scholarships
|
gen_6642aefe55f49c3528d31fbbceaa4e91
|
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine - Training and Development
|
Medical Research Council
|
London School of Hygiene and Tropical Medicine
|
HRCS22_00947
|
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine - Training and Development
|
HRCS Research Uncodeable / Studentship
| 1fellowships_scholarships
|
gen_30e43274afcc68fe23ceee643ce198e2
|
LSH&TM - Gambia (at LSH&TM) DTA - 2019-2029
|
Medical Research Council
|
London School of Hygiene and Tropical Medicine
|
HRCS22_00954
|
No abstract available for this analysis
|
HRCS Research Uncodeable / Studentship
| 1fellowships_scholarships
|
gen_726cc11abd906416e49217599e2820ac
|
8 - DTA - URVI Uganda (at LSH&TM)
|
Medical Research Council
|
MRC/UVRI and LSHTM Research Unit Uganda
|
HRCS22_01014
|
The Unit has established management and training structures that are used to ensure there is transparency and equity. These include the Unit Management Committee (UMC) whose membership includes the heads of programmes and sections (the UMC has approved TOR). The Unit has a Training Coordinator who coordinates training activities. At UMC meetings, training needs and the allocation of available resources are discussed and agreed upon. The process of presenting training applications to the UMC is as follows: any staff member, in discussion with their supervisor, can make a case for consideration for training. The Training Coordinator reviews applications and compiles cases for training to be put to the UMC. At the UMC decisions are by consensus. Approval is given on the basis of factors such as relevance to the Unit’s research portfolio, strength of the applicant and application, any previous support to the candidate and available funds. The courses considered include both PhD and Masters Courses. The PhD courses are fully funded and most of those taken on are enrolled at the London School of Hygiene and Tropical Medicine. The Masters courses are funded on a 50% MRC funded and 50% individual student sponsored basis. Consideration for these courses is based on many factors among which is relevance to Unit research and projects with the potential to ultimately result into innovative science.
|
HRCS Research Uncodeable / Studentship
| 1fellowships_scholarships
|
gen_5c12662be0c6811f00de24a36bf7ab34
|
Skills Developments Grant - Travel award - Advances in Ewing Ssarcoma Research conference 14 October 2022
|
Bone Cancer Research Trust
|
Essen University Hospital
|
HRCS22_11840
|
Poster presentation: ATR inhibitors in Ewing Sarcoma – Targeting DNA damage repair
|
5.1 Pharmaceuticals
| 1fellowships_scholarships
|
gen_5ee5639c77f625a091c5c8c530ac627a
|
Skills Developments Grant - Travel award - Advances in Ewing Ssarcoma Research conference 14 October 2022
|
Bone Cancer Research Trust
|
Georgetown University
|
HRCS22_11851
|
Oral presentation: Neuropeptide Y and its Y5 receptor in Ewing sarcoma metastasis
|
2.1 Biological and endogenous factors
| 1fellowships_scholarships
|
gen_72b562c447ae0b7f17d5243434562dd2
|
TUF Urolink Fellowship
|
The Urology Foundation
|
Unknown
|
HRCS22_11938
|
Visit to University Teaching Hospital, Lusaka, Zambia
|
HRCS Research Uncodeable
| 1fellowships_scholarships
|
gen_02f0665c6fa261e36b02cb73dcb0ea86
|
Decoding Genetic Studies from Pakistan - A Review of International, Regional and Local Guidelines and Compliance.
|
Wellcome Trust
|
Aga Khan University
|
HRCS22_12151
|
I conducted research for my Masters thesis to explore, identify and examine ethical guidelines available for genetic studies and to then analyse and describe the extent to which researchers in Pakistan, comply with existing ethical standards specified for genetic research. I report in my thesis that there are no guidelines for genetic research, gene therapy or gene editing in Pakistan. I also found some other patterns in the studies reviewed that I would like to present in the form of a publication in a peer reviewed journal as I feel they will provide a foundation of behavioural practises of researchers in Pakistan. I would also like to use the findings as a starting point to develop and propose guidelines for researchers for genetic research, gene therapy and gene editing in Pakistan. I want to propose guidelines that can be incorporated effectively into practise for which I will need to identify effective training, implementation and monitoring of the guidelines. Key goals: 1. Develop a better understanding of the ethical review process of international collaborations in the UK 2. Produce a draft of a paper for submission to a peer reviewed journal 3. Propose an outline of guidelines for researchers in Pakistan
|
No Research Activity assigned
| 1fellowships_scholarships
|
gen_2f112de7778e16039c77e1d5927ab477
|
Reducing meat intake to mitigate climate change and improve health
|
Wellcome Trust
|
University of North Carolina at Chapel Hill
|
HRCS22_12601
|
Black, Indigenous, and People of Color (BIPOC) suffer most from the consequences of broken food systems (Petersen et al., 2019) and climate change (Morello-Frosch et al., 2009) yet are underrepresented among research leaders working to address such issues (National Science Foundation, 2018; Pearson & Schuldt, 2014). The Nutrition Research Scholars Program (NRSP) aims to build a pipeline of BIPOC scholars to become leaders in food, health, and climate research to inform policy. Our activity will involve implementation of the pilot NRSP providing BIPOC students interested in nutrition and climate with research experience and mentorship from leaders in nutrition and food policy. We will implement a 12-week summer NRSP for two BIPOC undergraduate students to build research and professional development skills and prepare for matriculation in a PhD program. Short-term indicators of success will include objective measures (e.g., total professional development workshops and networking meetings attended) and subjective measures (e.g., satisfaction with the NRSP). Long-term indicators will include continuation of an annual NRSP, total scholars matriculating in related PhD programs, and development of a network of BIPOC scholars working with our research group. Upon successful completion of the pilot, we will expand the program to other research groups within the UNC Department of Nutrition; disseminate program findings at nutrition conferences; and build sustainability by incorporating funding for NRSP scholars in grant proposals. With time, the NRSP will foster a pipeline of BIPOC nutrition scholars pursuing graduate training to work as researchers at the nexus of food policy, health, and environmental change.
|
No Research Activity assigned
| 1fellowships_scholarships
|
gen_2a23239f5c7123679116cdedaf3c847e
|
ECFS & CFE Post-Doctoral Research Fellowship
|
Cystic Fibrosis Trust
|
European Cystic Fibrosis Society
|
HRCS22_12654
|
The European Cystic Fibrosis Society (ECFS) is an international societyof researchersand clinical professionals committed to improving survival and quality of life for people with cystic fibrosis (CF)by promoting high quality research, education and care.Cystic Fibrosis Europe (CFE) is the federation of national CF Associations in Europe. CFE represents persons with CF and their families in Europe. CFE aims to promote investment and progress in CF research in Europe, to promote the best care from a patient perspectiveand represent and defend the interests of people with CF.With aim to foster basic and translational research on CF, the ECFS and CFE have joined forces to support a number of European Post-Doctoral2-year duration Research Fellowships. It is likely that a call for this 2-year support will be launched every 2 years.
|
HRCS Research Uncodeable
| 1fellowships_scholarships
|
gen_f61d546a52309f738eb0d085334bac7c
|
AREF Training Programme Grant 2019/20
|
Medical Research Foundation
|
Atlanta Research and Education Foundation
|
HRCS22_12723
|
The aim of the Research Development Fellowship (RDF) Programme is to provide opportunities for talented health researchers based in Africa, so that they can lead research that is responsive to its African settings and can contribute to reducing the burden of disease. During the fellowship Fellows will have developed their skills, experience, confidence and research outputs to help them progress towards becoming an independent researcher and leading their own research programme
|
No Research Activity assigned
| 1fellowships_scholarships
|
gen_791d00f0a2befa415a32b50f5c8380b3
|
Inclusion and Equity in Humanitarianism: A Fellowship with Médecins Sans Frontières (MSF)
|
Wellcome Trust
|
University of Cape Town
|
HRCS22_12728
|
During my secondment with MSF, my project will focus on equity in humanitarian responses to global health emergencies. Humanitarian organisations such as MSF are a critical part of the international response to global health emergencies. Increasingly humanitarian organisations are required to reflect on equity within their work. Questions of equity relate to, amongst others, how MSF works with other actors such as governments, engagement activities with affected communities, provision of health care services, the role of technology and research-related activities. This project has three objectives: 1. Policy review: I will conduct a review of policies that guides the response of MSF with a specific focus on how equity is operationalised. 2. Critical review and analysis: I will conduct a review and critical analysis of literature related to equity in humanitarian responses in global health emergencies. This review will summarise normative and empirical accounts, frameworks, and considerations of equity, including research as part of the humanitarian response. 3. Recommendations: Based on insights gained from objectives 1 and 2, I will develop targeted recommendations regarding equity for relevant stakeholders involved in MSF's work. I will also facilitate interactive sessions with MSF staff about their experiences of equity, which will also inform recommendations.
|
8.3 Policy, ethics and research governance
| 1fellowships_scholarships
|
gen_105ac4a8599abbddd8205e7b8b1f8e02
|
David Hague Early Career Investigator of the Year Award
|
Alzheimer's Research UK
|
New York University
|
HRCS22_12780
|
No abstract available for this analysis.
|
No Research Activity assigned
| 1fellowships_scholarships
|
gen_02c086ece0e988ae90314066587c1697
|
Mindscapes Curatorial Research Fellow
|
Wellcome Trust
|
Humboldt-Universität zu Berlin
|
HRCS22_14768
|
Mindscapes Curatorial Research FellowFull-time position with CARMAH, reporting to the DirectorThis post-doctoral fellowship appointment will assist with the research and development phase of a new project looking at aspects of mental health with a specific focus on Berlin. Alongside pursuing self-directed research, the fellow will work closely with members of Wellcome’s International Cultural Programmes team and Wellcome’s Germany Office under the direction of the International Cultural Producer Danielle Olsen to: - Develop external partnerships across the city with partner organisations on the theme of mental health in Berlin investigating potential archives, collections, institutions and community led organisations that could provide a focus for transdisciplinary research - Serve as connector across participant spaces and places, developing creative new links with international city partners (in Bengaluru, New York and Tokyo) as the project develops - Assist in developing interdisciplinary and inclusive methods and processes between and across the Arts and Sciences on a mental health theme - Participate in a launch meeting in July 2021 on a mental health theme with a Berlin City focus - Explore crossover and hybrid experimental curatorial possibilities utilizing original creative work, events, and public programming.
|
8.1 Organisation and delivery of services
| 1fellowships_scholarships
|
gen_3056ce2f195498fd0cb390ad79c4b320
|
Kennedy Trust Chair in Molecular Immunology
|
The Kennedy Trust for Rheumatology Research
|
University of Oxford
|
HRCS22_20525
|
No abstract available for this analysis.
|
Personal
| 1fellowships_scholarships
|
gen_7d4222d07fab5d1c6a64d018c87b50e7
|
A 4 year PhD in theoretical systems biology and bioinformatics
|
Wellcome Trust
|
Imperial College London
|
HRCS22_20553
|
No abstract available for this analysis.
|
Studentships
| 1fellowships_scholarships
|
gen_d8bc18ea2bd4a8b8c56208d951394773
|
Wellcome Trust Four year PhD programme in Stem Cell Biology and Medicine
|
Wellcome Trust
|
University of Cambridge
|
HRCS22_20588
|
No abstract available for this analysis.
|
Studentships
| 1fellowships_scholarships
|
gen_5ef92cba50dd421404fc2a3a430d94b6
|
Wellcome Trust 4-year PhD Programme in Quantitative and Biophysical Biology
|
Wellcome Trust
|
University of Manchester
|
HRCS22_20600
|
No abstract available for this analysis.
|
Studentships
| 1fellowships_scholarships
|
gen_4607517a10efae93c7cda4e2d44f2f5e
|
KIR Director salary and research support
|
The Kennedy Trust for Rheumatology Research
|
University of Oxford
|
HRCS22_20610
|
No abstract available for this analysis.
|
Personal
| 1fellowships_scholarships
|
gen_77d9989a4272a92f197870ae50b27895
|
Infection, Immunology and Translational Medicine 4 year PhD programme.
|
Wellcome Trust
|
University of Oxford
|
HRCS22_20637
|
No abstract available for this analysis.
|
Studentships
| 1fellowships_scholarships
|
gen_0967ed46e802104428850d0e027e48e6
|
Translational Neuroscience - training the next generation of basic neuroscientists to embrace clinical research.
|
Wellcome Trust
|
University of Edinburgh
|
HRCS22_20659
|
No abstract available for this analysis.
|
Studentships
| 1fellowships_scholarships
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.